Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Publications indexed to the term Antibodies, Monoclonal

FacultyTitle
1Structural insights into single-pass transmembrane receptor GC-A activation by distinct antihypertensive antibodies. (Liu S, Manzo O, Wang J, Zhu L, Xiao F, Su YC, Kurre D, Liu W, Miao Y, Di Lorenzo A, Huang XY) Nat Commun 2026 Apr 06;17(1)    
1Predicting Early Mortality in Newly Diagnosed AL Amyloidosis: Development and Validation of the PACE Score for Daratumumab-Treated Patients. (Mellgard GS, Bazarbachi AH, Zanwar S, Hegenbart U, Bodanapu G, Bhutani D, Chen G, D'Souza A, Dispenzieri A, Gertz M, Kumar S, Lentzsch S, Milani P, Muchtar E, Palladini G, Trajanova D, Patwari A, Sanchorawala V, Mohty M, Wang S, Kastritis E, Theodorakakou F, Schönland S, Chakraborty R, Cowan AJ) Am J Hematol 2026 Apr;101(4):768-783       1 Citation
1Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims Analysis. (Obeidat AZ, Betz M, Farber RS, Goff E, Gudesblatt M, Hua LH, Mao-Draayer Y, Robertson D, Santoro JD, Wang T, Gomes D, Bozin I, Mendoza JP, Bian B, Lewin JB, Belviso N, Shankar SL) Adv Ther 2026 Apr;43(4):1653-1670       1 Citation
1Structural basis of HPA-1a alloimmunization in FNAIT and allosteric regulation of integrin conformation. (Zhang H, Paddock C, Oosterhoff JJ, Nguyen HTT, Zhi H, Wang Z, Sheridan D, Stuge TB, Ghevaert C, Newman DK, Vidarsson G, Newman PJ, Zhu J) Blood 2026 May 28;147(22):2569-2581       2 Citations
1Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial. (Einsele H, San-Miguel J, Dhakal B, Touzeau C, Leleu X, van de Donk NW, Sidana S, Oriol A, Cohen YC, Harrison SJ, Mateos MV, Martínez-López J, Corradini P, Karlin L, Chen D, Li Q, Yeh TM, Li K, Plaks V, Slaughter A, Lonardi C, Benachour N, Ghosh A, Vogel M, Schecter JM, Lendvai N, Koneru M, Patel N, Florendo E, Ho PJ, Popat R) Lancet Oncol 2026 Feb;27(2):254-268       36 Citations
1Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study. (Jindal T, Jiang CY, Alhalabi O, Davidsohn M, Freeman D, Epstein IY, Bakaloudi DR, Talukder R, Nizam A, Nguyen CB, Oh E, Tsung I, Glover MJ, Khaki AR, Taylor AK, Jaime-Casas S, Jang A, Lemke E, Pywell C, Evans ST, Shin D, Bilen MA, Basu A, Kilari D, Tripathi A, Brown J, Emamekhoo H, Davis NB, Shah S, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS) Urol Oncol 2026 Jan;44(1):65.e1-65.e11       1 Citation
1Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study. (Jiang CY, Hwang H, Epstein IY, Bakaloudi DR, Talukder R, Taylor AK, Nizam A, Jindal T, Glover MJ, Khaki AR, Barata PC, Nguyen CB, Oh E, Davis NB, Mabey H, Hoimes CJ, Evans ST, Abuqayas B, Lemke E, Tsung I, Qiao W, Kilari D, Zakharia Y, Bilen MA, Milowsky MI, Shah SA, Gupta S, Emamekhoo H, Bellmunt J, Alva AS, Grivas P, Msaouel P, Koshkin VS, Campbell MT, Alhalabi O) Oncologist 2025 Nov 11;30(11)    
1Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study. (Chari A, van de Donk NWCJ, Dholaria B, Weisel K, Mateos MV, Goldschmidt H, Martin TG, Morillo D, Reece D, Rodríguez-Otero P, Bhutani M, D'Souza A, Oriol A, Rosiñol L, Bahlis NJ, Vishwamitra D, Skerget S, Verona RI, Bakshi K, Kang L, Prior TJ, Vandenberk L, Tolbert J, Lee S, Smit MD, Wäsch R) Blood 2025 Dec 11;146(24):2902-2913       15 Citations
1Successful Treatment of Generalized Pustular Psoriasis With Spesolimab in Two Young Children. (Longnecker A, Foschi CM, Carlberg VM, Swanson L, Holland KE) Pediatr Dermatol 2026;43(2):382-386       1 Citation
1SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement. (Stein Gold L, Gottlieb AB, Armstrong AW, Alkousakis T, Bissonnette R, Langley RG, Krueger J, Papp K, Choi O, Rowland K, Chan D, Jeyarajah J, Park-Wyllie L, Gao LL, Gordon KB, Merola JF, Lebwohl MG, Strober B) Br J Dermatol 2026 Jan 06;194(1):25-36       5 Citations
1Real-World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1-3 Prior Lines of Therapy: Optum Database. (Dhakal B, Einsele H, Schecter JM, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Nair S, Varghese NE, He J, Kharat A, Lee S, Cost P, Potluri R, Koneru M, Patel N, Florendo E, Rodriguez-Otero P, Yong K) Cancer Med 2025 Aug;14(15):e71093       1 Citation
1Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial. (Lee JM, Miller A, Rose PG, AlHilli M, Washington C, John VS, Shah CA, Matsuo K, Siedel J, Miller DS, Hopp EE, O'Shea A, Chan JK, Bradford LS, Morse CB, Nagel CI, Rodabaugh KJ, Kohn EC, Moore KN, Liu JF) Clin Cancer Res 2025 Jun 13;31(12):2370-2378       9 Citations
2The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma. (Ahmed G, Hamadani M, Al-Juhaishi T) Expert Opin Biol Ther 2025;25(2):161-173       4 Citations
1Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data. (Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, Bakaloudi D, Davidsohn M, Freeman D, Glover M, Khaki AR, Evans S, Lemke E, Bose R, Sim W, Pywell C, Basu A, Kilari D, Barata PC, Bilen MA, Zakharia Y, Milowsky MI, Shah SA, Bellmunt J, Grivas P, Emamekhoo H, Davis NB, Gupta S, Hoimes C, Campbell MT, Alva A, Koshkin VS) Eur Urol Oncol 2025 Apr;8(2):258-262       8 Citations
1Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials. (Yong K, Einsele H, Schecter JM, Roccia T, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Connors K, Qi K, Londhe A, Carson R, Kharat A, Cost P, Valluri S, Mendes J, Pacaud L, Patel N, Florendo E, Dhakal B) Eur J Cancer 2025 Jan 17;215:115157       6 Citations
1Antigen-specific immunotherapy for platelet alloimmune disorders. (Newman DK, Newman PJ) Hum Immunol 2024 Nov;85(6):111172       7 Citations
1Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. (Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L, Wiechno P, Atduev V, Kann AG, Kim TH, Suárez C, Chang CH, Roghmann F, Özgüroğlu M, Eigl BJ, Oliveira N, Buchler T, Gadot M, Zakharia Y, Armstrong J, Gupta A, Hois S, van der Heijden MS, NIAGARA Investigators) N Engl J Med 2024 Nov 14;391(19):1773-1786       364 Citations
1Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC. (Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY) J Thorac Oncol 2025 Jan;20(1):109-118       21 Citations
1Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy. (Chakraborty R, Zanwar S, Hegenbart U, Bhutani D, Gertz MA, Dispenzieri A, Kumar S, D'Souza A, Patwari A, Cowan A, Chen G, Milani P, Palladini G, Sanchorawala V, Bodanapu G, Schönland SO, Lentzsch S, Muchtar E) Blood 2024 Dec 19;144(25):2613-2624       21 Citations
1Anti-mCD20 in combination with α-mCXCL13 monoclonal antibody inhibits anti-FVIII antibody development in hemophilia A mice. (Zheng Q, Lin K, Zhang N, Shi Q, Wu Y, Chen Y) Int Immunopharmacol 2024 Sep 30;139:112735       2 Citations
2Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. (Callander NS, Silbermann R, Kaufman JL, Godby KN, Laubach J, Schmidt TM, Sborov DW, Medvedova E, Reeves B, Dhakal B, Rodriguez C, Chhabra S, Chari A, Bal S, Anderson LD Jr, Dholaria BR, Nathwani N, Hari P, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Giri S, Costa LJ, Usmani SZ, Richardson PG, Voorhees PM) Blood Cancer J 2024 Apr 22;14(1):69       33 Citations
1Impact of osteoporosis and osteoporosis medications on fracture healing: a narrative review. (Chandran M, Akesson KE, Javaid MK, Harvey N, Blank RD, Brandi ML, Chevalley T, Cinelli P, Cooper C, Lems W, Lyritis GP, Makras P, Paccou J, Pierroz DD, Sosa M, Thomas T, Silverman S, Fracture Working Group of the Committee of Scientific Advisors of the International Osteoporosis Foundation, on behalf of the International Osteoporosis Foundation, Société Internationale de Chirurgie Orthopédique et de Traumatologie) Osteoporos Int 2024 Aug;35(8):1337-1358       61 Citations
1Inhibition of CD40L with Frexalimab in Multiple Sclerosis. (Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, Dufek M, Saubadu S, Bejuit R, Truffinet P, Djukic B, Wallstroem E, Giovannoni G, Frexalimab Phase 2 Trial Group) N Engl J Med 2024 Feb 15;390(7):589-600       84 Citations
1Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. (Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB) J Thorac Oncol 2024 Jun;19(6):928-940       49 Citations
1Association of Survival With Immune-Related Adverse Events-Time to Consider the Duration of Treatment. (Fujiwara Y, Cortellini A, Naqash AR) JAMA Dermatol 2024 Mar 01;160(3):368-369    
1Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. (Horita N, Fujiwara Y) N Engl J Med 2024 Jan 18;390(3):287       14 Citations
2Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity. (Faber ML, Oldham RAA, Thakur A, Rademacher MJ, Kubicka E, Dlugi TA, Gifford SA, McKillop WM, Schloemer NJ, Lum LG, Medin JA) Front Immunol 2023;14:1225610       15 Citations
1Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells. (Rodriguez Benavente MC, Hughes HB, Kremer PG, Subedi GP, Barb AW) Immunology 2023 Oct;170(2):202-213       7 Citations
1Treatment of thrombocytopenia and thrombosis in HIT in mice using deglycosylated KKO: a novel therapeutic? (Sarkar A, Khandelwal S, Koma GT, Kim H, Gruel Y, Rollin J, Passam F, Wool GD, Arepally GM, Cines DB, Rauova L, Poncz M) Blood Adv 2023 Aug 08;7(15):4112-4123       10 Citations
1Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study. (Epperla N, Welkie RL, Torka P, Shouse G, Karmali R, Shea L, Anampa-Guzmán A, Oh TS, Reaves H, Tavakkoli M, Lindsey K, Greenwell IB, Hansinger E, Thomas C, Chowdhury SM, Annunzio K, Christian B, Barta SK, Geethakumari PR, Bartlett NL, Herrera AF, Grover NS, Olszewski AJ) J Hematol Oncol 2023 May 08;16(1):49       20 Citations
1DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma. (Arend R, Dholakia J, Castro C, Matulonis U, Hamilton E, Jackson CG, LyBarger K, Goodman HM, Duska LR, Mahdi H, ElNaggar AC, Kagey MH, Liu A, Piper D, Barroilhet LM, Bradley W, Sachdev J, Sirard CA, O'Malley DM, Birrer M) Gynecol Oncol 2023 May;172:82-91       24 Citations
3A modified ELISA assay differentiates CCL20 locked dimers from wild-type monomers. (Wu X, Clarke WR, Koplinski CA, Peterson FC, Dwinell MB, Wei G, Chao E, Huynh M, Yamada D, Volkman BF, Hwang ST) J Immunol Methods 2023 Apr;515:113453       2 Citations
1Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023. (Joshi M, Tuanquin L, Zhu J, Walter V, Schell T, Kaag M, Kilari D, Liao J, Holder SL, Emamekhoo H, Sankin A, Merrill S, Zheng H, Warrick J, Hauke R, Gartrel B, Stein M, Drabick J, Degraff DJ, Zakharia Y) J Immunother Cancer 2023 Feb;11(2)       27 Citations
1Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. (Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Anderson LD Jr, Bal S, Dhakal B, Nathwani N, Shah N, Medvedova E, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Schmidt T, Orlowski RZ, Shain KH, Cowan AJ, Dholaria B, Cornell RF, Jerkins JH, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG, Voorhees PM) Transplant Cell Ther 2023 Mar;29(3):174.e1-174.e10       57 Citations
3Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy. (Furqan F, Maring M, Szabo A, Fenske TS, Hamadani M, Shah NN) Blood Adv 2023 Jun 13;7(11):2463-2467       7 Citations
1Analysis of College of American Pathologists von Willebrand Factor Proficiency Testing Program. (Salazar E, Long TA, Smock KJ, Wool GD, Rollins-Raval M, Chen D, Harris NS, Chan CW, Olson JD, Pham HP, Ritter J, Unold D, VanSandt AM, Goodwin Iv AJ) Semin Thromb Hemost 2022 Sep;48(6):690-699    
1Combining ablative radiotherapy and anti CD47 monoclonal antibody improves infiltration of immune cells in tumor microenvironments. (Rostami E, Bakhshandeh M, Ghaffari-Nazari H, Alinezhad M, Alimohammadi M, Alimohammadi R, Mahmoodi Chalbatani G, Hejazi E, Webster TJ, Tavakkol-Afshari J, Jalali SA) PLoS One 2022;17(8):e0273547       7 Citations
1Polymorphic Forms of Human Cytomegalovirus Glycoprotein O Protect against Neutralization of Fibroblast Entry by Antibodies Targeting Epitopes Defined by Glycoproteins H and L. (He L, Taylor S, Costa C, Görzer I, Kalser J, Fu TM, Freed D, Wang D, Cui X, Hertel L, McVoy MA) Viruses 2022 Jul 09;14(7)       6 Citations
1Simplified Lung Ultrasound Examination and Telehealth Feasibility in Early SARS-CoV-2 Infection. (Kimura BJ, Resnikoff PM, Tran EM, Bonagiri PR, Spierling Bagsic SR) J Am Soc Echocardiogr 2022 Oct;35(10):1047-1054       9 Citations
4Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. (Mohan M, Becnel MR, Shah UA, Dong H, Gundarlapalli S, Peterson T, Orozco JS, Horowitz S, Chhabra S, Dhakal B, Thanendrarajan S, Radhakrishnan SV, Al Hadidi S, Tan C, Mailankody S, Hultcrantz M, Korde N, Hassoun H, Lesokhin AM, Thomas SK, Patel KK, Manasanch EE, Weber DM, Szabo A, Kaufman GP, Lee HC, Zangari M, van Rhee F, Usmani SZ, D'Souza A, Orlowski RZ, Schinke C) Am J Hematol 2022 Jul;97(7):E276-E280       5 Citations
1A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. (Solomon B, Callejo A, Bar J, Berchem G, Bazhenova L, Saintigny P, Wunder F, Raynaud J, Girard N, Lee JJ, Sulaiman R, Prouse B, Bresson C, Ventura H, Magidi S, Rubin E, Young B, Onn A, Leyland-Jones B, Schilsky RL, Lazar V, Felip E, Kurzrock R) Cancer Med 2022 Jul;11(14):2790-2800       22 Citations
1Did brentuximab vedotin's rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results? (Hamadani M) Haematologica 2022 Jul 01;107(7):1500-1502    
1Myelin-associated glycoprotein activation triggers glutamate uptake by oligodendrocytes in vitro and contributes to ameliorate glutamate-mediated toxicity in vivo. (Vivinetto AL, Castañares C, Garcia-Keller C, Moyano AL, Falcon C, Palandri A, Rozés-Salvador V, Rojas JI, Patrucco L, Monferran C, Cancela L, Cristiano E, Schnaar RL, Lopez PHH) Biochim Biophys Acta Mol Basis Dis 2022 Apr 01;1868(4):166324       8 Citations
3Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. (Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D'Souza A, Hall A, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS) J Clin Oncol 2022 Sep 01;40(25):2901-2912       225 Citations
1Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. (Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS) Cancer 2022 Mar 15;128(6):1194-1205       86 Citations
1Multicentre evaluation of 5B9, a monoclonal anti-PF4/heparin IgG mimicking human HIT antibodies, as an internal quality control in HIT functional assays: Communication from the ISTH SSC Subcommittee on Platelet Immunology. (Pouplard C, Rollin J, Vayne C, Charuel N, Ahmadi Z, Alberio L, Azjenberg N, Althaus K, Bakchoul T, Chong B, Curtis BR, Faille D, Gomez FJ, Gresele P, Morel-Kopp MC, Mullier F, Nazy I, Smith JW, Greinacher A, Gruel Y) J Thromb Haemost 2022 Jan;20(1):252-259       13 Citations
6Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth. (Geethadevi A, Nair A, Parashar D, Ku Z, Xiong W, Deng H, Li Y, George J, McAllister DM, Sun Y, Kadamberi IP, Gupta P, Dwinell MB, Bradley WH, Rader JS, Rui H, Schwabe RF, Zhang N, Pradeep S, An Z, Chaluvally-Raghavan P) Cancer Res 2021 Oct 15;81(20):5336-5352       64 Citations
1Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series. (Lust H, Gong S, Remiker A, Rossoff J) Pediatr Blood Cancer 2021 Oct;68(10):e29261       31 Citations
1Burosumab treatment for fibrous dysplasia. (Gladding A, Szymczuk V, Auble BA, Boyce AM) Bone 2021 Sep;150:116004       42 Citations
1Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. (Blauvelt A, Gordon KB, Lee P, Bagel J, Sofen H, Lockshin B, Soliman AM, Geng Z, Zhan T, Alperovich G, Stein Gold L) J Dermatolog Treat 2022 Jun;33(4):2085-2093       14 Citations
1A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (Ribrag V, Lee ST, Rizzieri D, Dyer MJS, Fayad L, Kurzrock R, Andritsos L, Bouabdallah R, Hayat A, Bacon L, Jiang Y, Miah K, Delafont B, Hamid O, Anyanwu S, Martinez P, Hess B) Clin Lymphoma Myeloma Leuk 2021 May;21(5):309-317.e3       28 Citations
1Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials. (Augustin M, Lambert J, Zema C, Thompson EHZ, Yang M, Wu EQ, Garcia-Horton V, Geng Z, Valdes JM, Joshi A, Gordon KB) JAMA Dermatol 2020 Dec 01;156(12):1344-1353       47 Citations
1Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. (Putman M, Chock YPE, Tam H, Kim AHJ, Sattui SE, Berenbaum F, Danila MI, Korsten P, Sanchez-Alvarez C, Sparks JA, Coates LC, Palmerlee C, Peirce A, Jayatilleke A, Johnson SR, Kilian A, Liew J, Prokop LJ, Murad MH, Grainger R, Wallace ZS, Duarte-García A, COVID-19 Global Rheumatology Alliance) Arthritis Rheumatol 2021 Jan;73(1):36-47       50 Citations
1Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. (Strober B, Menter A, Leonardi C, Gordon K, Lambert J, Puig L, Photowala H, Longcore M, Zhan T, Foley P) J Eur Acad Dermatol Venereol 2020 Dec;34(12):2830-2838       63 Citations
1Anifrolumab in Systemic Lupus Erythematosus. (Putman M) N Engl J Med 2020 Apr 23;382(17):1665-1666    
1Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation. (Nikolaenko L, Chhabra S, Biran N, Chowdhury A, Hari PN, Krishnan A, Richter J) Clin Lymphoma Myeloma Leuk 2020 Jun;20(6):407-414       14 Citations
1Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. (van Rhee F, Casper C, Voorhees PM, Fayad LE, Gibson D, Kanhai K, Kurzrock R) Lancet Haematol 2020 Mar;7(3):e209-e217       62 Citations
1A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. (Kahl BS, Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E, Feingold JM, Ardeshna KM, Solh M, Heffner LT, Ungar D, He S, Boni J, Havenith K, O'Connor OA) Clin Cancer Res 2019 Dec 01;25(23):6986-6994       99 Citations
1Risankizumab in moderate-to-severe plaque psoriasis. (Serrano L, Maloney V, Gordon KB) Immunotherapy 2019 Nov;11(16):1357-1370       6 Citations
1Impact of Novel Monoclonal Antibody Therapeutics on Blood Bank Pretransfusion Testing. (Mei Z, Wool GD) Hematol Oncol Clin North Am 2019 Oct;33(5):797-811       12 Citations
1In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. (Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Kröger N, Luetkens T) Leukemia 2020 Jan;34(1):317-321       32 Citations
1A Long-Acting Neutralizing Monoclonal ACTH Antibody Blocks Corticosterone and Adrenal Gene Responses in Neonatal Rats. (Gehrand AL, Phillips J, Malott K, Raff H) Endocrinology 2019 Jul 01;160(7):1719-1730       22 Citations
1A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. (Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP) Blood Adv 2019 May 28;3(10):1568-1573       25 Citations
1The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models. (Zhou R, Wang S, Wen H, Wang M, Wu M) Exp Cell Res 2019 Jul 15;380(2):141-148       21 Citations
1Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. (Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, Ridinger-Saison M, DelGiorno KE, Antal CE, Liang G, Atkins AR, Erikson G, Sun H, Meisenhelder J, Terenziani E, Woo G, Fang L, Santisakultarm TP, Manor U, Xu R, Becerra CR, Borazanci E, Von Hoff DD, Grandgenett PM, Hollingsworth MA, Leblanc M, Umetsu SE, Collisson EA, Scadeng M, Lowy AM, Donahue TR, Reya T, Downes M, Evans RM, Wahl GM, Pawson T, Tian R, Hunter T) Nature 2019 May;569(7754):131-135       383 Citations
1Anti-CD24 Antibody-Nitric Oxide Conjugate Selectively and Potently Suppresses Hepatic Carcinoma. (Sun F, Wang Y, Luo X, Ma Z, Xu Y, Zhang X, Lv T, Zhang Y, Wang M, Huang Z, Zhang J) Cancer Res 2019 Jul 01;79(13):3395-3405       61 Citations
1Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. (Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ) Leukemia 2019 Sep;33(9):2266-2275       570 Citations
1Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. (Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA) J Am Acad Dermatol 2019 Apr;80(4):1029-1072       929 Citations
1Variation in Care in the Management of Children With Crohn's Disease: Data From a Multicenter Inception Cohort Study. (Krishnakumar C, Ballengee CR, Liu C, Kim MO, Baker SS, Baldassano RN, Cohen SA, Crandall WV, Denson LA, Dubinsky MC, Evans J, Gokhale R, Griffiths A, Guthery SL, Oliva-Hemker M, Heyman MB, Keljo D, Kellermayer R, Leleiko NS, Mack DR, Markowitz JF, Moulton DE, Noe JD, Otley AR, Patel AS, Pfefferkorn M, Rabizadeh S, Rosh JR, Snapper S, Walters TD, Ziring D, Mondal K, Kappelman MD, Hyams JS, Kugathasan S) Inflamm Bowel Dis 2019 Jun 18;25(7):1208-1217       21 Citations
1Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. (Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R) Eur J Cancer 2019 Jan;107:142-152       244 Citations
1IL-23 inhibitors for moderate-to-severe psoriasis. (Ibler E, Gordon KB) Semin Cutan Med Surg 2018 Sep;37(3):158-162       13 Citations
1International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. (van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC) Blood 2018 Nov 15;132(20):2115-2124       376 Citations
2Daratumumab in Primary Effusion Lymphoma. (Shah NN, Singavi AK, Harrington A) N Engl J Med 2018 Aug 16;379(7):689-690       36 Citations
1Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. (Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H) Lancet 2018 Aug 25;392(10148):650-661       627 Citations
1Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. (Wu YM, Cieślik M, Lonigro RJ, Vats P, Reimers MA, Cao X, Ning Y, Wang L, Kunju LP, de Sarkar N, Heath EI, Chou J, Feng FY, Nelson PS, de Bono JS, Zou W, Montgomery B, Alva A, PCF/SU2C International Prostate Cancer Dream Team, Robinson DR, Chinnaiyan AM) Cell 2018 Jun 14;173(7):1770-1782.e14       515 Citations
1Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials. (Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A) JAMA Dermatol 2018 Jun 01;154(6):676-683       118 Citations
1Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. (Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, You Y, Shen YK, Reich K) J Eur Acad Dermatol Venereol 2018 Nov;32(11):1940-1949       85 Citations
1Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer. (Aithal A, Junker WM, Kshirsagar P, Das S, Kaur S, Orzechowski C, Gautam SK, Jahan R, Sheinin YM, Lakshmanan I, Ponnusamy MP, Batra SK, Jain M) PLoS One 2018;13(4):e0193907       23 Citations
1Variation in nuclear size and PD-L2 positivity correlate with aggressive chromophobe renal cell carcinoma. (Mostafa ME, Abdelkader A, Kuroda N, Pérez-Montiel D, Banerjee A, Hes O, Iczkowski KA) Ann Diagn Pathol 2018 Jun;34:31-35       1 Citation
1Novel, Broadly Reactive Anticapsular Antibodies against Carbapenem-Resistant Klebsiella pneumoniae Protect from Infection. (Diago-Navarro E, Motley MP, Ruiz-Peréz G, Yu W, Austin J, Seco BMS, Xiao G, Chikhalya A, Seeberger PH, Fries BC) mBio 2018 Apr 03;9(2)       73 Citations
1Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials. (Gottlieb AB, Gordon K, Hsu S, Elewski B, Eichenfield LF, Kircik L, Rastogi S, Pillai R, Israel R) J Eur Acad Dermatol Venereol 2018 Aug;32(8):1305-1313       37 Citations
1Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. (Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, Pillai R, Israel RJ) Br J Dermatol 2018 Aug;179(2):320-328       73 Citations
1A comparison of human natural monoclonal antibodies and aptamer conjugates for promotion of CNS remyelination: where are we now and what comes next? (Perwein MK, Smestad JA, Warrington AE, Heider RM, Kaczor MW, Maher LJ 3rd, Wootla B, Kunbaz A, Rodriguez M) Expert Opin Biol Ther 2018 May;18(5):545-560       20 Citations
1Detecting Cell Surface Expression of the G Protein-Coupled Receptor CXCR4. (Nevins AM, Marchese A) Methods Mol Biol 2018;1722:151-164       8 Citations
1The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma. (Rezahosseini O, Hanaei S, Hamadani M, Keshavarz-Fathi M, Rezaei N) Int Rev Immunol 2018 May 04;37(3):165-173       5 Citations
1The dynamics of native Atoh7 protein expression during mouse retinal histogenesis, revealed with a new antibody. (Miesfeld JB, Glaser T, Brown NL) Gene Expr Patterns 2018 Jan;27:114-121       25 Citations
1Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. (Viswanathan HN, Mutebi A, Milmont CE, Gordon K, Wilson H, Zhang H, Klekotka PA, Revicki DA, Augustin M, Kricorian G, Nirula A, Strober B) Value Health 2017 Sep;20(8):1174-1179       12 Citations
1Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. (Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, Shen YK, You Y, Griffiths CEM) Br J Dermatol 2018 Jan;178(1):132-139       76 Citations
2The two novel DLL4-targeting antibody-drug conjugates MvM03 and MGD03 show potent anti-tumour activity in breast cancer xenograft models. (Wang S, Zhou R, Sun F, Li R, Wang M, Wu M) Cancer Lett 2017 Nov 28;409:125-136       12 Citations
1PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. (Kansy BA, Concha-Benavente F, Srivastava RM, Jie HB, Shayan G, Lei Y, Moskovitz J, Moy J, Li J, Brandau S, Lang S, Schmitt NC, Freeman GJ, Gooding WE, Clump DA, Ferris RL) Cancer Res 2017 Nov 15;77(22):6353-6364       210 Citations
1Natural immunoglobulin M initiates an inflammatory response important for both hepatic ischemia reperfusion injury and regeneration in mice. (Marshall K, Jin J, Atkinson C, Alawieh A, Qiao F, Lei B, Chavin KD, He S, Tomlinson S) Hepatology 2018 Feb;67(2):721-735       33 Citations
1A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. (Dispenzieri A, D'Souza A, Gertz MA, Laumann K, Wiseman G, Lacy MQ, LaPlant B, Buadi F, Hayman SR, Kumar SK, Dingli D, Hogan WJ, Ansell SM, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Johnston PB, Litzow MR, Witzig TE) Bone Marrow Transplant 2017 Oct;52(10):1372-1377       13 Citations
1Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. (Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R) Mol Cancer Ther 2017 Nov;16(11):2598-2608       1946 Citations
1Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease. (Cohen PR, Kato S, Goodman AM, Ikeda S, Kurzrock R) Int J Mol Sci 2017 Jul 31;18(8)       34 Citations
1Structural insights into the extracellular recognition of the human serotonin 2B receptor by an antibody. (Ishchenko A, Wacker D, Kapoor M, Zhang A, Han GW, Basu S, Patel N, Messerschmidt M, Weierstall U, Liu W, Katritch V, Roth BL, Stevens RC, Cherezov V) Proc Natl Acad Sci U S A 2017 Aug 01;114(31):8223-8228       59 Citations
1Biofunctionalized Hybrid Magnetic Gold Nanoparticles as Catalysts for Photothermal Ablation of Colorectal Liver Metastases. (White SB, Kim DH, Guo Y, Li W, Yang Y, Chen J, Gogineni VR, Larson AC) Radiology 2017 Dec;285(3):809-819       28 Citations
4Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm. (Raychaudhuri R, Riese MJ, Bylow K, Burfeind J, Mackinnon AC, Tolat PP, Iczkowski KA, Kilari D) Clin Genitourin Cancer 2017 Oct;15(5):e897-e901       15 Citations
1Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer: NRG Oncology RTOG 0839. (Edelman MJ, Hu C, Le QT, Donington JS, D'Souza WD, Dicker AP, Loo BW, Gore EM, Videtic GMM, Evans NR, Leach JW, Diehn M, Feigenberg SJ, Chen Y, Paulus R, Bradley JD) J Thorac Oncol 2017 Sep;12(9):1413-1420       21 Citations
1Comparative Evaluation of αCD40 (2C10R4) and αCD154 (5C8H1 and IDEC-131) in a Nonhuman Primate Cardiac Allotransplant Model. (OʼNeill NA, Zhang T, Braileanu G, Sun W, Cheng X, Hershfeld A, Laird CT, Kronfli A, Hock LA, Dahi S, Kubicki N, Sievert E, Hassanein W, Cimeno A, Pierson RN 3rd, Azimzadeh AM) Transplantation 2017 Sep;101(9):2038-2047       19 Citations
1Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. (Sharabi A, Kim SS, Kato S, Sanders PD, Patel SP, Sanghvi P, Weihe E, Kurzrock R) Oncologist 2017 Jun;22(6):631-637       107 Citations
1Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo. (Ma Z, He H, Sun F, Xu Y, Huang X, Ma Y, Zhao H, Wang Y, Wang M, Zhang J) J Cancer Res Clin Oncol 2017 Oct;143(10):1929-1940       35 Citations
2PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. (Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM) Blood 2017 Jul 13;130(2):221-228       228 Citations
1Teprotumumab for Thyroid-Associated Ophthalmopathy. (Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS) N Engl J Med 2017 May 04;376(18):1748-1761       696 Citations
1PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. (Sunshine JC, Nguyen PL, Kaunitz GJ, Cottrell TR, Berry S, Esandrio J, Xu H, Ogurtsova A, Bleich KB, Cornish TC, Lipson EJ, Anders RA, Taube JM) Clin Cancer Res 2017 Aug 15;23(16):4938-4944       139 Citations
1BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. (Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, Abruzzo L, Gordon A, Mantel R, Smith LL, McWhorter S, Davis M, Doong TJ, Ny F, Lucas M, Chase W, Jones JA, Flynn JM, Maddocks K, Rogers K, Jaglowski S, Andritsos LA, Awan FT, Blum KA, Grever MR, Lozanski G, Johnson AJ, Byrd JC) J Clin Oncol 2017 May 01;35(13):1437-1443       451 Citations
1Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. (Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R) Clin Cancer Res 2017 Aug 01;23(15):4242-4250       777 Citations
1Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. (Moy JD, Moskovitz JM, Ferris RL) Eur J Cancer 2017 May;76:152-166       92 Citations
1JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease. (Patel M, Ikeda S, Pilat SR, Kurzrock R) JAMA Dermatol 2017 May 01;153(5):449-452       11 Citations
1Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. (Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB) J Am Acad Dermatol 2017 Mar;76(3):418-431       708 Citations
1Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients. (Kurzrock R, Stewart DJ) Clin Cancer Res 2017 Mar 01;23(5):1137-1148       45 Citations
1Immune--Mediated Colitis with Novel Immunotherapy : PD-1 Inhibitor Associated Gastrointestinal Toxicity. (Gondal B, Patel P, Gallan A, Hart J, Bissonnette M) Acta Gastroenterol Belg 2016;79(2):379-381       3 Citations
1Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. (Kharfan-Dabaja MA, El-Asmar J, Awan FT, Hamadani M, Ayala E) Best Pract Res Clin Haematol 2016 Mar;29(1):54-66       7 Citations
1Targeting CD38 in Refractory Extranodal Natural Killer Cell-T-Cell Lymphoma. (Hari P, Raj RV, Olteanu H) N Engl J Med 2016 Oct 13;375(15):1501-1502       95 Citations
1Anti-TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy. (Voelker J, Berg PH, Sheetz M, Duffin K, Shen T, Moser B, Greene T, Blumenthal SS, Rychlik I, Yagil Y, Zaoui P, Lewis JB) J Am Soc Nephrol 2017 Mar;28(3):953-962       266 Citations
2Development of Novel Immunotherapies for Multiple Myeloma. (Al-Hujaily EM, Oldham RA, Hari P, Medin JA) Int J Mol Sci 2016 Sep 08;17(9)       23 Citations
1A humanized anti-DLL4 antibody promotes dysfunctional angiogenesis and inhibits breast tumor growth. (Jia X, Wang W, Xu Z, Wang S, Wang T, Wang M, Wu M) Sci Rep 2016 Jun 15;6:27985       27 Citations
1Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry. (Tran EE, Nelson EA, Bonagiri P, Simmons JA, Shoemaker CJ, Schmaljohn CS, Kobinger GP, Zeitlin L, Subramaniam S, White JM) J Virol 2016 Sep 01;90(17):7618-27       31 Citations
1IL-6 Inhibition With MEDI5117 Decreases The Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence. (Finkel KA, Warner KA, Kerk S, Bradford CR, McLean SA, Prince ME, Zhong H, Hurt EM, Hollingsworth RE, Wicha MS, Tice DA, Nör JE) Neoplasia 2016 May;18(5):273-281       24 Citations
1VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer. (Xie W, Liu F, Wang Y, Ren X, Wang T, Chen Z, Tang M, Sun F, Li Z, Wang M, Zhang J) Oncotarget 2016 Mar 29;7(13):16445-61       21 Citations
3Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset. (Cabrera SM, Wang X, Chen YG, Jia S, Kaldunski ML, Greenbaum CJ, Type 1 Diabetes TrialNet Canakinumab Study Group, Mandrup-Poulsen T, AIDA Study Group, Hessner MJ) Eur J Immunol 2016 Apr;46(4):1030-46       52 Citations
1Can selectin and iNKT cell therapies meet the needs of people with sickle cell disease? (Field JJ) Hematology Am Soc Hematol Educ Program 2015;2015:426-32       5 Citations
1Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease. (Fajgenbaum DC, Kurzrock R) Immunotherapy 2016;8(1):17-26       27 Citations
2Emerging immunotherapy in pediatric lymphoma. (Erker C, Harker-Murray P, Burke MJ) Future Oncol 2016 Jan;12(2):257-70       5 Citations
1Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. (Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, Raghav K, Subbiah V, Hess K, Meric-Bernstam F, Hong DS, Overman MJ) BMC Cancer 2015 Oct 16;15:713       46 Citations
1In vitro testing of an anti-CD40 monoclonal antibody, clone 2C10, in primates and pigs. (Lee W, Satyananda V, Iwase H, Tanaka T, Miyagawa Y, Long C, Ayares D, Cooper DK, Hara H) Transpl Immunol 2015 Nov;33(3):185-91       8 Citations
1American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. (Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E) Biol Blood Marrow Transplant 2015 Dec;21(12):2039-2051       166 Citations
1Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. (Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A) N Engl J Med 2015 Oct;373(14):1318-28       791 Citations
1Infliximab Therapy for Corticosteroid-Resistant Ipilimumab-Induced Colitis. (Beniwal-Patel P, Matkowskyj K, Caldera F) J Gastrointestin Liver Dis 2015 Sep;24(3):274       8 Citations
1Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTS-13. (Deforche L, Roose E, Vandenbulcke A, Vandeputte N, Feys HB, Springer TA, Mi LZ, Muia J, Sadler JE, Soejima K, Rottensteiner H, Deckmyn H, De Meyer SF, Vanhoorelbeke K) J Thromb Haemost 2015 Nov;13(11):2063-75       73 Citations
1A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. (van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R) Oncotarget 2015 Oct 06;6(30):30408-19       66 Citations
1Structural basis for quinine-dependent antibody binding to platelet integrin αIIbβ3. (Zhu J, Zhu J, Bougie DW, Aster RH, Springer TA) Blood 2015 Oct 29;126(18):2138-45       27 Citations
1Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? (Epperla N, Fenske TS, Lazarus HM, Hamadani M) Bone Marrow Transplant 2015 Nov;50(11):1393-404       9 Citations
1A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. (Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K) N Engl J Med 2015 Jul 09;373(2):136-44       292 Citations
1Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. (Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke B, West JS, Neuenburg JK, James DF, Hall N, Johnson AJ, Byrd JC) Blood 2015 Aug 13;126(7):842-50       123 Citations
1The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. (Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A) Oncologist 2015 Jul;20(7):737-41       15 Citations
1Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report. (Mohammed A, Janku F, Qi M, Kurzrock R) J Med Case Rep 2015 Feb 28;9:45       5 Citations
1Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. (Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R) Invest New Drugs 2015 Jun;33(3):621-31       62 Citations
1IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice. (Schwenk R, DeBot M, Porter M, Nikki J, Rein L, Spaccapelo R, Crisanti A, Wightman PD, Ockenhouse CF, Dutta S) PLoS One 2014;9(10):e111020       61 Citations
1The role of integrin antagonists in the treatment of inflammatory bowel disease. (Beniwal-Patel P, Saha S) Expert Opin Biol Ther 2014 Dec;14(12):1815-23       5 Citations
1Unmet needs in the treatment of psoriasis. (Kragballe K, van de Kerkhof PC, Gordon KB) Eur J Dermatol 2014;24(5):523-32       21 Citations
1Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. (Liu S, Meng X, Chen H, Liu W, Miller T, Murph M, Lu Y, Zhang F, Gagea M, Arteaga CL, Mills GB, Meric-Bernstam F, González-Angulo AM) Oncotarget 2014 Oct 15;5(19):9049-64       23 Citations
2Mice with an absent stress response are protected against ischemic renal injury. (Sreedharan R, Chen S, Miller M, Haribhai D, Williams CB, Van Why SK) Kidney Int 2014 Sep;86(3):515-24       12 Citations
1MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. (Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R) Lancet Oncol 2014 May;15(6):656-66       191 Citations
1Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. (Liu X, Lorusso P, Mita M, Piha-Paul S, Hong DS, Fu S, McQuinn L, Asatiani E, Doyle LA, Chen HX, Hess KR, Kurzrock R, Naing A) Oncologist 2014 Apr;19(4):426-8       11 Citations
1A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. (Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, van de Velde H, Tromp B, Vermeulen J, Kurzrock R) Clin Cancer Res 2014 Apr 15;20(8):2192-204       184 Citations
1Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation. (Pilch NA, Taber DJ, Moussa O, Thomas B, Denmark S, Meadows HB, McGillicuddy JW, Srinivas TR, Baliga PK, Chavin KD) Ann Surg 2014 May;259(5):888-93       42 Citations
1Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. (Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJ, Swart RE, Walker MS, Haluska P, Munster PN, Marshall J, Hamid O, Kurzrock R) Cancer Chemother Pharmacol 2014 Mar;73(3):467-73       37 Citations
1Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. (Gordon KB, Kimball AB, Chau D, Viswanathan HN, Li J, Revicki DA, Kricorian G, Ortmeier BG) Br J Dermatol 2014 Mar;170(3):705-15       45 Citations
1Rationale and early clinical data on IL-17 blockade in psoriasis. (Nwe SM, Champlain AH, Gordon KB) Expert Rev Clin Immunol 2013 Jul;9(7):677-82       15 Citations
1Imatinib tackles lymphoma via the PDGFRβ+ pericyte. (Chute JP, Himburg HA) Blood 2013 Jun 27;121(26):5107-8       9 Citations
1Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. (Jiang Y, Janku F, Subbiah V, Angelo LS, Naing A, Anderson PM, Herzog CE, Fu S, Benjamin RS, Kurzrock R) Oncotarget 2013 Jun;4(6):884-9       31 Citations
1A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. (Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F) Clin Cancer Res 2013 Jul 01;19(13):3659-70       197 Citations
1Inhibition of HPA-1a alloantibody-mediated platelet destruction by a deglycosylated anti-HPA-1a monoclonal antibody in mice: toward targeted treatment of fetal-alloimmune thrombocytopenia. (Bakchoul T, Greinacher A, Sachs UJ, Krautwurst A, Renz H, Harb H, Bein G, Newman PJ, Santoso S) Blood 2013 Jul 18;122(3):321-7       45 Citations
1Monoclonal antibodies in conditioning regimens for hematopoietic cell transplantation. (Kharfan-Dabaja MA, Nishihori T, Otrock ZK, Haidar N, Mohty M, Hamadani M) Biol Blood Marrow Transplant 2013 Sep;19(9):1288-300       12 Citations
2Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. (Kearl TJ, Jing W, Gershan JA, Johnson BD) J Immunol 2013 Jun 01;190(11):5620-8       88 Citations
1Association between ipilimumab and celiac disease. (Gentile NM, D'Souza A, Fujii LL, Wu TT, Murray JA) Mayo Clin Proc 2013 Apr;88(4):414-7       60 Citations
1Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. (Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, Stadtmauer EA, Mineshi S, Ambinder R, Fenske T, Horowitz M, Fisher R, Tomblyn M) J Clin Oncol 2013 May 01;31(13):1662-8       144 Citations
2Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. (Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R) Br J Cancer 2013 Mar 05;108(4):826-30       117 Citations
1Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. (Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D, Valdes J, Setze C, Strober B) J Eur Acad Dermatol Venereol 2013 Oct;27(10):1252-61       64 Citations
1PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. (Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M, PSOLAR investigators and Steering Committee) J Drugs Dermatol 2012 Oct;11(10):1210-7       86 Citations
1Porcine sperm bind to specific 6-sialylated biantennary glycans to form the oviduct reservoir. (Kadirvel G, Machado SA, Korneli C, Collins E, Miller P, Bess KN, Aoki K, Tiemeyer M, Bovin N, Miller DJ) Biol Reprod 2012 Jun;87(6):147       69 Citations
1Human anti-varicella-zoster virus (VZV) recombinant monoclonal antibody produced after Zostavax immunization recognizes the gH/gL complex and neutralizes VZV infection. (Birlea M, Owens GP, Eshleman EM, Ritchie A, Traktinskiy I, Bos N, Seitz S, Azarkh Y, Mahalingam R, Gilden D, Cohrs RJ) J Virol 2013 Jan;87(1):415-21       20 Citations
1Case series demonstrating improvement in chronic cutaneous sarcoidosis following treatment with TNF inhibitors. (Wanat KA, Rosenbach M) Arch Dermatol 2012 Sep;148(9):1097-100       32 Citations
2Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo. (Shi Q, Kuether EL, Schroeder JA, Perry CL, Fahs SA, Cox Gill J, Montgomery RR) J Thromb Haemost 2012 Nov;10(11):2328-37       25 Citations
1Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy. (Sareen D, Ebert AD, Heins BM, McGivern JV, Ornelas L, Svendsen CN) PLoS One 2012;7(6):e39113       128 Citations
1Targeting regulatory T cells in the treatment of type 1 diabetes mellitus. (Cabrera SM, Rigby MR, Mirmira RG) Curr Mol Med 2012 Dec;12(10):1261-72       50 Citations
1Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. (Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R) Clin Cancer Res 2012 May 01;18(9):2625-31       187 Citations
1An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. (Reich K, Papp KA, Griffiths CE, Szapary PO, Yeilding N, Wasfi Y, Ott E, Hsu MC, Lebwohl M, Gordon KB, PHOENIX 1, PHOENIX 2, and ACCEPT investigators) J Drugs Dermatol 2012 Mar;11(3):300-12       78 Citations
1Signaling through L-selectin mediates enhanced chemotaxis of lymphocyte subsets to secondary lymphoid tissue chemokine. (Subramanian H, Grailer JJ, Ohlrich KC, Rymaszewski AL, Loppnow JJ, Kodera M, Conway RM, Steeber DA) J Immunol 2012 Apr 01;188(7):3223-36       35 Citations
1Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. (Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, Guzzo C, Li S, Papp KA) Br J Dermatol 2012 Apr;166(4):861-72       133 Citations
1CD9 tetraspanin interacts with CD36 on the surface of macrophages: a possible regulatory influence on uptake of oxidized low density lipoprotein. (Huang W, Febbraio M, Silverstein RL) PLoS One 2011;6(12):e29092       54 Citations
1Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy. (Munoz J, Hong D, Kurzrock R) Int J Hematol 2012 Jan;95(1):1-2       4 Citations
2Flow cytometric analysis of surface light chain expression patterns in B-cell lymphomas using monoclonal and polyclonal antibodies. (Horna P, Olteanu H, Kroft SH, Harrington AM) Am J Clin Pathol 2011 Dec;136(6):954-9       38 Citations
1R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis. (Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, Parsons HA, Trent JC, Kurzrock R) PLoS One 2011;6(10):e26060       38 Citations
1A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. (Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, Williams DA, Gu Y, Valdes JM) J Invest Dermatol 2012 Feb;132(2):304-14       158 Citations
1Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. (Gordon KB, Papp KA, Langley RG, Ho V, Kimball AB, Guzzo C, Yeilding N, Szapary PO, Fakharzadeh S, Li S, Hsu MC, Reich K) J Am Acad Dermatol 2012 May;66(5):742-51       139 Citations
1Insulin-like growth factor 1 receptor (IGF-1R) inhibitor: another arrow in the quiver - Will it hit the moving target? (Subbiah V, Angelo LS, Kurzrock R) Expert Opin Investig Drugs 2011 Nov;20(11):1471-7       2 Citations
1Choosing first-line therapy for chronic lymphocytic leukemia. (Jaglowski S, Jones JA) Expert Rev Anticancer Ther 2011 Sep;11(9):1379-90       17 Citations
1Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. (Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, Menter A) JAMA 2011 Aug 24;306(8):864-71       279 Citations
2Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. (Hallett WH, Jing W, Drobyski WR, Johnson BD) Biol Blood Marrow Transplant 2011 Aug;17(8):1133-45       148 Citations
1Phase 1 clinical trials for sarcomas: the cutting edge. (Subbiah V, Kurzrock R) Curr Opin Oncol 2011 Jul;23(4):352-60       33 Citations
1Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. (Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, Morrow PK, Koenig K, Kurzrock R) J Clin Oncol 2011 Jul 01;29(19):e572-5       66 Citations
1Castleman's disease: from basic mechanisms to molecular therapeutics. (El-Osta HE, Kurzrock R) Oncologist 2011;16(4):497-511       134 Citations
4Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling. (Gao C, Boylan B, Fang J, Wilcox DA, Newman DK, Newman PJ) Blood 2011 May 05;117(18):4946-52       123 Citations
1Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia. (Brinkerhoff BT, Poetker DM, Choong NW) N Engl J Med 2011 Feb 17;364(7):688-9       33 Citations
1Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment. (Piha-Paul SA, Hong DS, Kurzrock R) J Clin Oncol 2011 Apr 20;29(12):e333-5       13 Citations
1Strong CD28 costimulation suppresses induction of regulatory T cells from naive precursors through Lck signaling. (Semple K, Nguyen A, Yu Y, Wang H, Anasetti C, Yu XZ) Blood 2011 Mar 17;117(11):3096-103       80 Citations
1Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. (Camacho LH, Garcia S, Panchal AM, Lim J, Hong DS, Ng C, Madoff DC, Fu S, Gayed I, Kurzrock R) Clin Colorectal Cancer 2010 Dec;9(5):311-4       10 Citations
1Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. (Kimball AB, Gordon KB, Langley RG, Menter A, Perdok RJ, Valdes J, ABT-874 Study Investigators) J Am Acad Dermatol 2011 Feb;64(2):263-74       27 Citations
1Concomitant trastuzumab with thoracic radiotherapy: a morphological and functional study. (Yavas G, Yildiz F, Guler S, Sargon MF, Yildiz D, Yolcu T, Tuncer M, Akyol FH) Ann Oncol 2011 May;22(5):1120-1126       13 Citations
1A first-in-human study of conatumumab in adult patients with advanced solid tumors. (Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, Juan G, Hwang YC, Wong S, Hill JS, Friberg G, LoRusso PM) Clin Cancer Res 2010 Dec 01;16(23):5883-91       128 Citations
1Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients. (Cheng YC, Valero V, Davis ML, Green MC, Gonzalez-Angulo AM, Theriault RL, Murray JL, Hortobagyi GN, Ueno NT) Br J Cancer 2010 Oct 26;103(9):1331-4       8 Citations
1Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy. (Fuller CK, Charlson JA, Dankle SK, Russell TJ) J Am Acad Dermatol 2010 Oct;63(4):e83-4       37 Citations
1Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors. (Cohen PR, Escudier SM, Kurzrock R) Am J Clin Dermatol 2011 Feb 01;12(1):63-7       38 Citations
1Endothelin signaling via guanine exchange factor C3G in renal glomerular mesangial cells. (Rufanova VA, Alexanian A, Ostendorf T, Bokemeyer D, Prosser S, Miller B, Sorokin A) Can J Physiol Pharmacol 2010 Aug;88(8):808-16       4 Citations
1Anti-CD25 antibody (daclizumab) maintenance therapy in pancreas transplantation. (Kirchner VA, Suszynski TM, Radosevich DM, Humar A, Dunn TB, Hill MJ, Finger EB, Sutherland DE, Kandaswamy R) Transplant Proc 2010;42(6):2003-5       6 Citations
1Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. (van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R) J Clin Oncol 2010 Aug 10;28(23):3701-8       223 Citations
2Identification, characterization and immunogenicity of an O-antigen capsular polysaccharide of Francisella tularensis. (Apicella MA, Post DM, Fowler AC, Jones BD, Rasmussen JA, Hunt JR, Imagawa S, Choudhury B, Inzana TJ, Maier TM, Frank DW, Zahrt TC, Chaloner K, Jennings MP, McLendon MK, Gibson BW) PLoS One 2010 Jul 06;5(7):e11060       86 Citations
1The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. (Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC) Blood 2010 Nov 11;116(19):3705-14       110 Citations
1Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. (Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM) J Am Acad Dermatol 2010 Sep;63(3):448-56       152 Citations
1A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. (Tsimberidou AM, Fu S, Ng C, Lim JA, Wen S, Hong D, Wheler J, Bedikian AY, Eng C, Wallace M, Camacho LH, Kurzrock R) Cancer 2010 Sep 01;116(17):4086-94       32 Citations
1The evolving use of bead arrays for platelet antibody detection. (Curtis BR) Transfusion 2010 Jul;50(7):1406-7    
1Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. (Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, Ortonne JP, Gordon KB, Kimball AB) J Am Acad Dermatol 2010 Sep;63(3):457-65       209 Citations
3Efficacy and safety of long-term (>7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia. (Olteanu H, Harrington AM, Ramirez S, Kroft SH, Hari P) Br J Haematol 2010 Aug;150(4):480-1       5 Citations
1Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. (Gandhi M, Alwawi E, Gordon KB) Semin Cutan Med Surg 2010 Mar;29(1):48-52       58 Citations
1Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. (Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK) Ophthalmology 2010 Jun;117(6):1064-1077.e35       1339 Citations
1Angioedema occurring in pediatric patients with Crohn disease treated with adalimumab. (Adamiak T, Stephens M, Werlin SL) J Pediatr Gastroenterol Nutr 2010 Aug;51(2):223-5       3 Citations
1A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. (Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, Eckhardt SG, Eid JE, Greig G, Habben K, McCarthy CD, Gore L) Clin Cancer Res 2010 Apr 15;16(8):2458-65       178 Citations
1Rituximab in chronic lymphocytic leukemia. (Jaglowski SM, Byrd JC) Semin Hematol 2010 Apr;47(2):156-69       34 Citations
1Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of the literature. (D'Souza A, Wilson J, Mukherjee S, Jaiyesimi I) Clin Lymphoma Myeloma Leuk 2010 Feb;10(1):E1-9       52 Citations
1Intracranial hemorrhage following neuroendovascular procedures with abciximab is associated with high mortality: a multicenter series. (Walsh RD, Barrett KM, Aguilar MI, Lanzino G, Hanel RA, Miller DA, Chong BW, Freeman WD) Neurocrit Care 2011 Aug;15(1):85-95       39 Citations
1A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. (Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D) Clin Cancer Res 2010 Feb 15;16(4):1256-63       157 Citations
1Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? (Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM) Oncologist 2010;15(2):130-41       110 Citations
1Combining targeted therapies: practical issues to consider at the bench and bedside. (Rodon J, Perez J, Kurzrock R) Oncologist 2010;15(1):37-50       50 Citations
1IL-6 and MYC collaborate in plasma cell tumor formation in mice. (Rutsch S, Neppalli VT, Shin DM, DuBois W, Morse HC 3rd, Goldschmidt H, Janz S) Blood 2010 Mar 04;115(9):1746-54       47 Citations
1Ranibizumab for coloboma-related choroidal neovascular membrane in a child. (Goodwin P, Shields CL, Ramasubramanian A, Brown GC, Shields JA) J AAPOS 2009 Dec;13(6):616-7       18 Citations
2Tracheoesophageal fistula associated with bevacizumab 21 months after completion of radiation therapy. (Gore E, Currey A, Choong N) J Thorac Oncol 2009 Dec;4(12):1590-1       23 Citations
1Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. (Dubinsky MC, Mei L, Friedman M, Dhere T, Haritunians T, Hakonarson H, Kim C, Glessner J, Targan SR, McGovern DP, Taylor KD, Rotter JI) Inflamm Bowel Dis 2010 Aug;16(8):1357-66       127 Citations
1The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine. (Krilov LR, Weiner LB, Yogev R, Fergie J, Katz BZ, Henrickson KJ, Welliver RC Sr) Pediatrics 2009 Dec;124(6):1682-4       25 Citations
1Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. (Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, Sanchez V, Dugger TC, de Matos Granja N, Narasanna A, Cook RS, Kennedy JP, Lindsley CW, Arteaga CL) Clin Cancer Res 2009 Dec 01;15(23):7266-76       116 Citations
1Impact of prior irregular infliximab dosing on performance of long-term infliximab maintenance therapy in Crohn's disease. (Stein DJ, Ananthakrishnan AN, Issa M, Williams JB, Beaulieu DB, Zadvornova Y, Ward A, Johnson K, Knox JF, Skaros S, Binion DG) Inflamm Bowel Dis 2010 Jul;16(7):1173-9       20 Citations
1Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. (Francia G, Man S, Lee CJ, Lee CR, Xu P, Mossoba ME, Emmenegger U, Medin JA, Kerbel RS) Clin Cancer Res 2009 Oct 15;15(20):6358-66       40 Citations
1New low-frequency platelet glycoprotein polymorphisms associated with neonatal alloimmune thrombocytopenia. (Peterson JA, Gitter ML, Kanack A, Curtis B, McFarland J, Bougie D, Aster R) Transfusion 2010 Feb;50(2):324-33       44 Citations
3Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. (Fenske TS, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chen YB, Freytes CO, Gale RP, Hale GA, Ilhan O, Khoury HJ, Lister J, Maharaj D, Marks DI, Munker R, Pecora AL, Rowlings PA, Shea TC, Stiff P, Wiernik PH, Winter JN, Rizzo JD, van Besien K, Lazarus HM, Vose JM) Biol Blood Marrow Transplant 2009 Nov;15(11):1455-64       53 Citations
1T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. (Iclozan C, Yu Y, Liu C, Liang Y, Yi T, Anasetti C, Yu XZ) Biol Blood Marrow Transplant 2010 Feb;16(2):170-8       95 Citations
1Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. (Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, Pfefferkorn MD, Kelleher KT, Griffiths AM, Kugathasan S, Keljo D, Oliva-Hemker M, Crandall W, Carvalho RS, Mack DR, Hyams JS) Am J Gastroenterol 2009 Dec;104(12):3042-9       120 Citations
1Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. (Patel B, Kirkland KE, Szydlo R, Pearce RM, Clark RE, Craddock C, Liakopoulou E, Fielding AK, Mackinnon S, Olavarria E, Potter MN, Russell NH, Shaw BE, Cook G, Goldstone AH, Marks DI) Haematologica 2009 Oct;94(10):1399-406       29 Citations
1Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. (Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, Sanchez V, Nolting DD, Buck JR, Zhao P, Ansari MS, Baldwin RM, Gore JC, Schiff R, Arteaga CL, Manning HC) Clin Cancer Res 2009 Jul 15;15(14):4712-21       78 Citations
1Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. (Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS) J Clin Oncol 2009 Jul 20;27(21):3557-65       232 Citations
1Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. (Ling HT, Field JJ, Blinder MA) Am J Hematol 2009 Jul;84(7):418-21       57 Citations
3Combined intravitreal anti-VEGF and verteporfin photodynamic therapy for juxtafoveal and extrafoveal choroidal neovascularization as an alternative to laser photocoagulation. (Han DP, McAllister JT, Weinberg DV, Kim JE, Wirostko WJ) Eye (Lond) 2010 Apr;24(4):713-6       20 Citations
1Durability of infliximab in Crohn's disease: a single-center experience. (Gonzaga JE, Ananthakrishnan AN, Issa M, Beaulieu DB, Skaros S, Zadvornova Y, Johnson K, Otterson MF, Binion DG) Inflamm Bowel Dis 2009 Dec;15(12):1837-43       20 Citations
2Complete and durable response of choroid metastasis from non-small cell lung cancer with systemic bevacizumab and chemotherapy. (George B, Wirostko WJ, Connor TB, Choong NW) J Thorac Oncol 2009 May;4(5):661-2       38 Citations
1Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. (Ratanatharathorn V, Logan B, Wang D, Horowitz M, Uberti JP, Ringden O, Gale RP, Khoury H, Arora M, Spellman S, Cutler C, Antin J, Bornhaüser M, Hale G, Verdonck L, Cairo M, Gupta V, Pavletic S, Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA) Br J Haematol 2009 Jun;145(6):816-24       66 Citations
1Autoimmune neutropenia in adults. (Akhtari M, Curtis B, Waller EK) Autoimmun Rev 2009 Sep;9(1):62-6       94 Citations
1Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. (Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, Harari PM) Clin Cancer Res 2009 Mar 01;15(5):1585-92       88 Citations
1Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. (Burmester GR, Mease P, Dijkmans BA, Gordon K, Lovell D, Panaccione R, Perez J, Pangan AL) Ann Rheum Dis 2009 Dec;68(12):1863-9       188 Citations
1Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. (Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J, Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group) Arch Ophthalmol 2009 Jan;127(1):13-21       88 Citations
1Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. (Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, ANCHOR Study Group) Ophthalmology 2009 Jan;116(1):57-65.e5       1287 Citations
1Transient anti-CD40L co-stimulation blockade prevents immune responses against human bullous pemphigoid antigen 2: implications for gene therapy. (Lanschuetzer CM, Olasz EB, Lazarova Z, Yancey KB) J Invest Dermatol 2009 May;129(5):1203-7       14 Citations
1Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. (Nand S, Godwin J, Smith S, Barton K, Michaelis L, Alkan S, Veerappan R, Rychlik K, Germano E, Stiff P) Leuk Lymphoma 2008 Nov;49(11):2141-7       59 Citations
1One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. (Mueller BU, Bennett CM, Feldman HA, Bussel JB, Abshire TC, Moore TB, Sawaf H, Loh ML, Rogers ZR, Glader BE, McCarthy MC, Mahoney DH, Olson TA, Feig SA, Lorenzana AN, Mentzer WC, Buchanan GR, Neufeld EJ, Pediatric Rituximab/ITP Study Group, Glaser Pediatric Research Network) Pediatr Blood Cancer 2009 Feb;52(2):259-62       51 Citations
1Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? (Ferreri AJ, Dognini GP, Govi S, Crocchiolo R, Bouzani M, Bollinger CR, D'Incan M, Delaporte E, Hamadani M, Jardin F, Martusewicz-Boros M, Montanari M, Szomor A, Zucca E, Cavalli F, Ponzoni M) J Clin Oncol 2008 Nov 01;26(31):5134-6; author reply 5136-7       69 Citations
1Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. (Rodon J, DeSantos V, Ferry RJ Jr, Kurzrock R) Mol Cancer Ther 2008 Sep;7(9):2575-88       148 Citations
1High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. (Hamadani M, Benson DM Jr, Lin TS, Porcu P, Blum KA, Devine SM) Eur J Haematol 2008 Dec;81(6):425-31       28 Citations
3Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. (Bredeson CN, Zhang MJ, Agovi MA, Bacigalupo A, Bahlis NJ, Ballen K, Brown C, Chaudhry MA, Horowitz MM, Kurian S, Quinlan D, Muehlenbien CE, Russell JA, Savoie L, Rizzo JD, Stewart DA) Biol Blood Marrow Transplant 2008 Sep;14(9):993-1003       79 Citations
1Successful treatment of aggressive HIV-associated multicentric Castleman's disease: a case report. (Flejsierowicz M, Ahmed MS, Kotov P, Cheng YC) WMJ 2008 Jul;107(4):191-4       8 Citations
1Short-term response to adalimumab in childhood inflammatory bowel disease. (Noe JD, Pfefferkorn M) Inflamm Bowel Dis 2008 Dec;14(12):1683-7       38 Citations
1What's new in clinical pharmacology and therapeutics. (Chawla PS, Kochar MS) WMJ 2008 Apr;107(2):76-83    
1Rethinking eligibility creep. (Kazanis M, Leonardi C, Gordon K, Strober B, Menter A, Kimball AB) J Am Acad Dermatol 2008 Jul;59(1):165-7; author reply 167       1 Citation
1Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. (Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J, De Marzo AM) Mod Pathol 2008 Sep;21(9):1156-67       375 Citations
1Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. (Hamadani M, Hofmeister CC, Jansak B, Phillips G, Elder P, Blum W, Penza S, Lin TS, Klisovic R, Marcucci G, Farag SS, Devine SM) Biol Blood Marrow Transplant 2008 Jul;14(7):783-9       55 Citations
1Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia. (Tholouli E, Liakopoulou E, Greenfield HM, Shaw BE, Tauro S, Byrne JL, Dennis M, Burthem J, Lucas GS, Craddock C, Russell NH, Liu Yin JA) Br J Haematol 2008 Jun;142(2):318-20       7 Citations
1Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). (Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB, PHOENIX 1 study investigators) Lancet 2008 May 17;371(9625):1665-74       1611 Citations
1Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). (Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K, PHOENIX 2 study investigators) Lancet 2008 May 17;371(9625):1675-84       1422 Citations
1Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. (Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A) J Am Acad Dermatol 2008 May;58(5):851-64       419 Citations
1Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. (Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R) J Am Acad Dermatol 2008 May;58(5):826-50       1264 Citations
1Using structural analysis to generate parasite-selective monoclonal antibodies. (Kron MA, Cichanowicz S, Hendrick A, Liu A, Leykam J, Kuhn LA) Protein Sci 2008 Jun;17(6):983-9       4 Citations
1Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. (Ingram W, Devereux S, Das-Gupta EP, Russell NH, Haynes AP, Byrne JL, Shaw BE, McMillan A, Gonzalez J, Ho A, Mufti GJ, Pagliuca A) Br J Haematol 2008 Apr;141(2):235-43       43 Citations
1Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. (Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM) Oncogene 2008 Jun 26;27(28):3944-56       493 Citations
1Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. (Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J, ABT-874 Psoriasis Study Investigators) Arch Dermatol 2008 Feb;144(2):200-7       221 Citations
1Active crohn disease and hypercalcemia treated with infliximab: case report and literature review. (Ioachimescu AG, Bauer TW, Licata A) Endocr Pract 2008;14(1):87-92       13 Citations
1Duration of remission of biologic agents for chronic plaque psoriasis. (Langley RG, Gordon KB) J Drugs Dermatol 2007 Dec;6(12):1205-12       18 Citations
1Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. (Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ) J Clin Oncol 2008 Jan 10;26(2):196-203       149 Citations
1The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines. (Lyu MA, Kurzrock R, Rosenblum MG) Biochem Pharmacol 2008 Feb 15;75(4):836-46       19 Citations
1Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. (Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M) J Dermatolog Treat 2007;18(6):341-50       96 Citations
1Bevacizumab in glaucoma: a review. (Ichhpujani P, Ramasubramanian A, Kaushik S, Pandav SS) Can J Ophthalmol 2007 Dec;42(6):812-5    
1Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. (Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR, MARINA Study Group) Arch Ophthalmol 2007 Nov;125(11):1460-9       213 Citations
1Bevacizumab therapy in patients with recurrent uterine neoplasms. (Wright JD, Powell MA, Rader JS, Mutch DG, Gibb RK) Anticancer Res 2007;27(5B):3525-8       41 Citations
1Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. (Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K) J Am Acad Dermatol 2008 Jan;58(1):106-15       855 Citations
1Cutaneous castleman's disease responds to anti interleukin-6 treatment. (Ahmed B, Tschen JA, Cohen PR, Zaki MH, Rady PL, Tyring SK, Corringham RE, Kurzrock R) Mol Cancer Ther 2007 Sep;6(9):2386-90       49 Citations
1Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. (Marble DJ, Gordon KB, Nickoloff BJ) J Dermatol Sci 2007 Nov;48(2):87-101       69 Citations
1Case reports: efalizumab-associated lymphoproliferative disease. (Bommakanti S, Patil A, Eshoa C, Chitambar CR) J Drugs Dermatol 2007 Jun;6(6):646-8       14 Citations
1Dramatic response to single-agent rituximab in a patient with intravascular lymphoma. (Vrindavanam N, Hamadani M, Steele B, Awan F, Suster S, Benson DM Jr) Am J Hematol 2007 Dec;82(12):1120-1       2 Citations
1A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. (Wright JD, Secord AA, Numnum TM, Rocconi RP, Powell MA, Berchuck A, Alvarez RD, Gibb RK, Trinkaus K, Rader JS, Mutch DG) Int J Gynecol Cancer 2008;18(3):400-6       37 Citations
1Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. (Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group) Ophthalmology 2007 Oct;114(10):1868-75       210 Citations
1Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab. (Das-Gupta EP, Russell NH, Shaw BE, Pearce RM, Byrne JL) Biol Blood Marrow Transplant 2007 Jun;13(6):724-33       11 Citations
1Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. (Schwartz CL, Gorlick R, Teot L, Krailo M, Chen Z, Goorin A, Grier HE, Bernstein ML, Meyers P, Children's Oncology Group) J Clin Oncol 2007 May 20;25(15):2057-62       119 Citations
1Chimerism does not predict for outcome after alemtuzumab based conditioning. (Michaelis L, Lin S, Joseph L, Artz AS, Kline J, Pollyea D, Stock W, Rich E, Collins-Jones D, Casey B, Del Cerro P, van Besien K) Bone Marrow Transplant 2007 Jul;40(2):181       7 Citations
1Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. (Czito BG, Bendell JC, Willett CG, Morse MA, Blobe GC, Tyler DS, Thomas J, Ludwig KA, Mantyh CR, Ashton J, Yu D, Hurwitz HI) Int J Radiat Oncol Biol Phys 2007 Jun 01;68(2):472-8       136 Citations
1CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. (Johnson BD, Jing W, Orentas RJ) J Immunother 2007;30(2):203-14       57 Citations
1Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. (Willett CG, Duda DG, di Tomaso E, Boucher Y, Czito BG, Vujaskovic Z, Vlahovic G, Bendell J, Cohen KS, Hurwitz HI, Bentley R, Lauwers GY, Poleski M, Wong TZ, Paulson E, Ludwig KA, Jain RK) Nat Clin Pract Oncol 2007 May;4(5):316-21       51 Citations
1The impact of chimerism patterns and predonor leukocyte infusion lymphopenia on survival following T cell-depleted reduced intensity conditioned transplants. (Shaw BE, Byrne JL, Das-Gupta E, Carter GI, Russell NH) Biol Blood Marrow Transplant 2007 May;13(5):550-9       25 Citations
1Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen. (Zheng J, Kohler ME, Chen Q, Weber J, Khan J, Johnson BD, Orentas RJ) BMC Immunol 2007 Mar 30;8:4       11 Citations
1Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. (Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, Evans DB, Vauthey JN, Xie K, Yao JC) Cancer 2007 Apr 15;109(8):1478-86       205 Citations
1Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma. (Williams KM, Higman MA, Chen AR, Schwartz CL, Wharam M, Colombani P, Arceci RJ) Pediatr Blood Cancer 2008 Mar;50(3):667-70       23 Citations
1Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target. (Camp ER, Yang A, Gray MJ, Fan F, Hamilton SR, Evans DB, Hooper AT, Pereira DS, Hicklin DJ, Ellis LM) Cancer 2007 Mar 15;109(6):1030-9       91 Citations
1Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. (Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR, MARINA Study Group) Ophthalmology 2007 Feb;114(2):246-52       388 Citations
1Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). (Gonzalez RJ, Buzdar AU, Fraser Symmans W, Yen TW, Broglio KR, Lucci A, Esteva FJ, Yin G, Kuerer HM) Breast J 2007;13(1):72-5       25 Citations
1Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy. (Field JJ, Fenske TS, Blinder MA) Haemophilia 2007 Jan;13(1):46-50       35 Citations
1Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. (Gong J, Yang D, Kohanim S, Humphreys R, Broemeling L, Kurzrock R) Mol Cancer Ther 2006 Dec;5(12):2991-3000       33 Citations
1Ranibizumab versus verteporfin for neovascular age-related macular degeneration. (Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group) N Engl J Med 2006 Oct 05;355(14):1432-44       3443 Citations
1Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. (Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM) J Am Acad Dermatol 2006 Oct;55(4):598-606       495 Citations
1Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma. (Burke MJ, Cohn SL) Pediatr Blood Cancer 2008 Mar;50(3):679-80       18 Citations
1Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. (Kahl BS, Longo WL, Eickhoff JC, Zehnder J, Jones C, Blank J, McFarland T, Bottner W, Rezazedeh H, Werndli J, Bailey HH, Wisconsin Oncology Network) Ann Oncol 2006 Sep;17(9):1418-23       99 Citations
1Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. (Wright JD, Hagemann A, Rader JS, Viviano D, Gibb RK, Norris L, Mutch DG, Powell MA) Cancer 2006 Jul 01;107(1):83-9       124 Citations
1Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. (Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, Caro I, Walicke PA, Wang X, Menter A, Efalizumab Study Group) Int J Dermatol 2006 May;45(5):605-14       72 Citations
1Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I. (Pariser DM, Gordon KB, Papp KA, Leonardi CL, Kwon P, Compton PG, Rundle AC, Walicke PA, Lebwohl M) J Cutan Med Surg 2005 Dec;9(6):303-12       30 Citations
1Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. (Wright JD, Viviano D, Powell MA, Gibb RK, Mutch DG, Grigsby PW, Rader JS) Gynecol Oncol 2006 Nov;103(2):489-93       100 Citations
1The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. (Crane CH, Varadhachary G, Wolff RA, Pisters PW, Evans DB) Best Pract Res Clin Gastroenterol 2006 Apr;20(2):365-82       46 Citations
1Effect of N-methyl-d-aspartate receptor blockade on plasticity of frontal cortex after cholinergic deafferentation in rat. (Garrett JE, Kim I, Wilson RE, Wellman CL) Neuroscience 2006 Jun 19;140(1):57-66       14 Citations
1Reversible posterior leukoencephalopathy syndrome and bevacizumab. (Ozcan C, Wong SJ, Hari P) N Engl J Med 2006 Mar 02;354(9):980-2; discussion 980-2    
1Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. (Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O'Reilly M, Lee JE, Wolff RA) J Clin Oncol 2006 Mar 01;24(7):1145-51       200 Citations
1The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. (Gordon KB, Ruderman EM) J Am Acad Dermatol 2006 Mar;54(3 Suppl 2):S85-91       36 Citations
1Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. (Papp KA, Miller B, Gordon KB, Caro I, Kwon P, Compton PG, Leonardi CL, Efalizumab Study Group) J Am Acad Dermatol 2006 Apr;54(4 Suppl 1):S164-70       39 Citations
1Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. (du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS) Clin Cancer Res 2006 Feb 01;12(3 Pt 1):904-16       131 Citations
1Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. (Aster RH, Curtis BR, Bougie DW, Dunkley S, Greinacher A, Warkentin TE, Chong BH, Scientific and Standardization Committee of The International Society On Thrombosis and Haemostasis) J Thromb Haemost 2006 Mar;4(3):678-9       64 Citations
1Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. (Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, Sawaf H, Moore TB, Loh ML, Glader BE, McCarthy MC, Mueller BU, Olson TA, Lorenzana AN, Mentzer WC, Buchanan GR, Feldman HA, Neufeld EJ) Blood 2006 Apr 01;107(7):2639-42       209 Citations
1Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. (Langley RG, Carey WP, Rafal ES, Tyring SK, Caro I, Wang X, Wetherill G, Gordon KB) Clin Ther 2005 Sep;27(9):1317-28       57 Citations
1Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. (McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, Wilding G) Clin Cancer Res 2005 Nov 01;11(21):7851-60       145 Citations
1131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. (Pagel JM, Appelbaum FR, Eary JF, Rajendran J, Fisher DR, Gooley T, Ruffner K, Nemecek E, Sickle E, Durack L, Carreras J, Horowitz MM, Press OW, Gopal AK, Martin PJ, Bernstein ID, Matthews DC) Blood 2006 Mar 01;107(5):2184-91       155 Citations
1The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. (Gordon KB, Bonish BK, Patel T, Leonardi CL, Nickoloff BJ) Br J Dermatol 2005 Nov;153(5):945-53       60 Citations
1Toxic epidermal necrolysis in two rhesus macaques (Macaca mulatta) after administration of rituximab. (Allen KP, Funk AJ, Mandrell TD) Comp Med 2005 Aug;55(4):377-81       14 Citations
1Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. (Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM) Cancer Res 2005 Sep 01;65(17):7775-81       141 Citations
1Progression of classic Kaposi's sarcoma with rituximab. (Clifford KS, Demierre MF) J Am Acad Dermatol 2005 Jul;53(1):155-7       29 Citations
1Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. (Kröger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Binder T, Eiermann T, Madrigal A, Schwerdtfeger R, Kiehl M, Sayer HG, Beyer J, Bornhäuser M, Ayuk F, Zander AR, Marks DI, Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group) Br J Haematol 2005 Jun;129(5):631-43       105 Citations
1Uncommon conundrum in common variable immunodeficiency. (Cunningham-Rundles C, Routes JM, Hostoffer R, Sullivan KE) Clin Immunol 2005 Sep;116(3):208-10       4 Citations
1Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. (Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB) Br J Dermatol 2005 May;152(5):954-60       125 Citations
1B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study. (Kessler CM, Gill JC, White GC 2nd, Shapiro A, Arkin S, Roth DA, Meng X, Lusher JM) Haemophilia 2005 Mar;11(2):84-91       64 Citations
1Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. (Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB, Efalizumab Study Group) J Am Acad Dermatol 2005 Mar;52(3 Pt 1):425-33       225 Citations
1Aging and cholinergic deafferentation alter GluR1 expression in rat frontal cortex. (Kim I, Wilson RE, Wellman CL) Neurobiol Aging 2005 Jul;26(7):1073-81       16 Citations
1Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. (Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W) Arch Dermatol 2005 Jan;141(1):31-8       215 Citations
1Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. (Gottlieb AB, Gordon KB, Lebwohl MG, Caro I, Walicke PA, Li N, Leonardi CL, EFALIZUMAB STUDY GROUP) J Drugs Dermatol 2004;3(6):614-24       80 Citations
1Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. (Mehandru S, Wrin T, Galovich J, Stiegler G, Vcelar B, Hurley A, Hogan C, Vasan S, Katinger H, Petropoulos CJ, Markowitz M) J Virol 2004 Dec;78(24):14039-42       73 Citations
1Thrombocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors. (Aster RH, Curtis BR, Bougie DW) Semin Thromb Hemost 2004 Oct;30(5):569-77       33 Citations
1Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin. (Albert MH, Yu XZ, Martin PJ, Anasetti C) Blood 2005 Feb 01;105(3):1355-61       20 Citations
1Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. (Patel T, Gordon KB) Dermatol Ther 2004;17(5):427-31       68 Citations
3Alpha phenyl-tert-butyl nitrone (PBN) protects syngeneic marrow transplant recipients from the lethal cytokine syndrome occurring after agonistic CD40 antibody administration. (Gendelman M, Halligan N, Komorowski R, Logan B, Murphy WJ, Blazar BR, Pritchard KA Jr, Drobyski WR) Blood 2005 Jan 01;105(1):428-31       10 Citations
1NKG2D receptor-mediated NK cell function is regulated by inhibitory Ly49 receptors. (Regunathan J, Chen Y, Wang D, Malarkannan S) Blood 2005 Jan 01;105(1):233-40       54 Citations
1Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. (Cheung WC, Kim JS, Linden M, Peng L, Van Ness B, Polakiewicz RD, Janz S) J Clin Invest 2004 Jun;113(12):1763-73       100 Citations
1Successful treatment of systemic and central nervous system lymphomatoid granulomatosis with rituximab. (Zaidi A, Kampalath B, Peltier WL, Vesole DH) Leuk Lymphoma 2004 Apr;45(4):777-80       54 Citations
4Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. (Boylan B, Chen H, Rathore V, Paddock C, Salacz M, Friedman KD, Curtis BR, Stapleton M, Newman DK, Kahn ML, Newman PJ) Blood 2004 Sep 01;104(5):1350-5       151 Citations
1Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. (Curtis BR, Divgi A, Garritty M, Aster RH) J Thromb Haemost 2004 Jun;2(6):985-92       81 Citations
1Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results. (Burke GW 3rd, Kaufman DB, Millis JM, Gaber AO, Johnson CP, Sutherland DE, Punch JD, Kahan BD, Schweitzer E, Langnas A, Perkins J, Scandling J, Concepcion W, Stegall MD, Schulak JA, Gores PF, Benedetti E, Danovitch G, Henning AK, Bartucci MR, Smith S, Fitzsimmons WE) Transplantation 2004 Apr 27;77(8):1269-75       79 Citations
1Mantle cell lymphoma in lymph nodes with metastatic small cell carcinoma of lung: a diagnostic and treatment dilemma. (Kampalath B, Abed N, Chitambar CR, Vantuinen P, Chakrabarty G, Hanson G, Rao RN, Shidham VB, Chang CC) Leuk Lymphoma 2004 Feb;45(2):409-14       13 Citations
1Effects of complete immunotoxin lesions of the cholinergic basal forebrain on fear conditioning and spatial learning. (Frick KM, Kim JJ, Baxter MG) Hippocampus 2004;14(2):244-54       58 Citations
1Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. (Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M) Blood 2004 Aug 01;104(3):655-8       123 Citations
1Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia. (Rosenblum MD, LaBelle JL, Chang CC, Margolis DA, Schauer DW, Vesole DH) Blood 2004 Mar 01;103(5):1969-71       46 Citations
1Lck is required for activation-induced T cell death after TCR ligation with partial agonists. (Yu XZ, Levin SD, Madrenas J, Anasetti C) J Immunol 2004 Feb 01;172(3):1437-43       17 Citations
1A new era in rheumatoid arthritis treatment. (Costello JC, Halverson PB) WMJ 2003;102(7):29-33       15 Citations
1Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder. (Ganne V, Siddiqi N, Kamaplath B, Chang CC, Cohen EP, Bresnahan BA, Hariharan S) Clin Transplant 2003 Oct;17(5):417-22       82 Citations
1Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. (Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A, Efalizumab Study Group) JAMA 2003 Dec 17;290(23):3073-80       391 Citations
1Severe hidradenitis suppurativa treated with infliximab infusion. (Adams DR, Gordon KB, Devenyi AG, Ioffreda MD) Arch Dermatol 2003 Dec;139(12):1540-2       99 Citations
1The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. (Shaw BE, Peggs K, Bird JM, Cavenagh J, Hunter A, Alejandro Madrigal J, Russell NH, Sirohi B, Towlson K, Williams CD, Marks DI, Clinical Trials Committee of the British Society of Blood and Marrow Transplantation) Br J Haematol 2003 Dec;123(5):886-95       24 Citations
1The ER-lumenal domain of the HHV-7 immunoevasin U21 directs class I MHC molecules to lysosomes. (Hudson AW, Blom D, Howley PM, Ploegh HL) Traffic 2003 Dec;4(12):824-37       32 Citations
1Autocrine lymphotoxin production in Epstein-Barr virus-immortalized B cells: induction via NF-kappaB activation mediated by EBV-derived latent membrane protein 1. (Thompson MP, Aggarwal BB, Shishodia S, Estrov Z, Kurzrock R) Leukemia 2003 Nov;17(11):2196-201       16 Citations
1Phase II study of alemtuzumab in chronic lymphoproliferative disorders. (Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ) Cancer 2003 Aug 15;98(4):773-8       127 Citations
1Dermatologic manifestations of Crohn disease in children: response to infliximab. (Kugathasan S, Miranda A, Nocton J, Drolet BA, Raasch C, Binion DG) J Pediatr Gastroenterol Nutr 2003 Aug;37(2):150-4       96 Citations
1Cell biology of laryngeal epithelial defenses in health and disease: further studies. (Johnston N, Bulmer D, Gill GA, Panetti M, Ross PE, Pearson JP, Pignatelli M, Axford SE, Dettmar PW, Koufman JA) Ann Otol Rhinol Laryngol 2003 Jun;112(6):481-91       179 Citations
3Mechanisms of endotoxin tolerance in human intestinal microvascular endothelial cells. (Ogawa H, Rafiee P, Heidemann J, Fisher PJ, Johnson NA, Otterson MF, Kalyanaraman B, Pritchard KA Jr, Binion DG) J Immunol 2003 Jun 15;170(12):5956-64       71 Citations
1Catheter-directed thrombolytic therapy in peripheral artery occlusions: combining reteplase and abciximab. (Drescher P, McGuckin J, Rilling WS, Crain MR) AJR Am J Roentgenol 2003 May;180(5):1385-91       21 Citations
1CD28 signal enhances apoptosis of CD8 T cells after strong TCR ligation. (Yu XZ, Martin PJ, Anasetti C) J Immunol 2003 Mar 15;170(6):3002-6       31 Citations
1Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225. (Sclabas GM, Fujioka S, Schmidt C, Fan Z, Evans DB, Chiao PJ) J Gastrointest Surg 2003 Jan;7(1):37-43; discussion 43       65 Citations
1Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy. (Holbrook JT, Jabs DA, Weinberg DV, Lewis RA, Davis MD, Friedberg D, Studies of Ocular Complications of AIDS (SOCA) Research Group) Arch Ophthalmol 2003 Jan;121(1):99-107       98 Citations
3Oxidative stress-induced iron signaling is responsible for peroxide-dependent oxidation of dichlorodihydrofluorescein in endothelial cells: role of transferrin receptor-dependent iron uptake in apoptosis. (Tampo Y, Kotamraju S, Chitambar CR, Kalivendi SV, Keszler A, Joseph J, Kalyanaraman B) Circ Res 2003 Jan 10;92(1):56-63       151 Citations
1Oligodendroglioma: pathology and molecular biology. (Engelhard HH, Stelea A, Cochran EJ) Surg Neurol 2002 Aug;58(2):111-7; discussion 117       83 Citations
1Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. (Kugathasan S, Levy MB, Saeian K, Vasilopoulos S, Kim JP, Prajapati D, Emmons J, Martinez A, Kelly KJ, Binion DG) Am J Gastroenterol 2002 Jun;97(6):1408-14       127 Citations
1Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. (Frank DW, Vallis A, Wiener-Kronish JP, Roy-Burman A, Spack EG, Mullaney BP, Megdoud M, Marks JD, Fritz R, Sawa T) J Infect Dis 2002 Jul 01;186(1):64-73       142 Citations
1The cysteine knot of platelet glycoprotein Ib beta (GPIb beta) is critical for the interaction of GPIb beta with GPIX. (Kenny D, Morateck PA, Montgomery RR) Blood 2002 Jun 15;99(12):4428-33       18 Citations
1Biologic therapy for psoriasis: the new therapeutic frontier. (Singri P, West DP, Gordon KB) Arch Dermatol 2002 May;138(5):657-63       107 Citations
1Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. (Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH) Blood 2002 Mar 15;99(6):2054-9       119 Citations
1Initial experience with the combination of reteplase and abciximab for thrombolytic therapy in peripheral arterial occlusive disease: a pilot study. (Drescher P, Crain MR, Rilling WS) J Vasc Interv Radiol 2002 Jan;13(1):37-43       34 Citations
2Donor natural killer (NK1.1+) cells do not play a role in the suppression of GVHD or in the mediation of GVL reactions after DLI. (Johnson BD, Dagher N, Stankowski WC, Hanke CA, Truitt RL) Biol Blood Marrow Transplant 2001;7(11):589-95       11 Citations
5Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. (Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D, Burns WH, Margolis DA, Vesole DH, Horowitz M, Zhang MJ, Juckett M, Drobyski WR) Biol Blood Marrow Transplant 2001;7(11):620-30       58 Citations
1Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis. (Runkel L, De Dios C, Karpusas M, Baker D, Li Z, Zafari M, Betzenhauser M, Muldowney C, Miller S, Redlich PN, Grossberg SE, Whitty A, Hochman PS) J Interferon Cytokine Res 2001 Nov;21(11):931-41       29 Citations
1Differential roles of CD36 and alphavbeta5 integrin in photoreceptor phagocytosis by the retinal pigment epithelium. (Finnemann SC, Silverstein RL) J Exp Med 2001 Nov 05;194(9):1289-98       127 Citations
1Protein phosphatase 2Calpha expression in normal human tissues: an immunohistochemical study. (Lifschitz-Mercer B, Sheinin Y, Ben-Meir D, Bramante-Schreiber L, Leider-Trejo L, Karby S, Smorodinsky NI, Lavi S) Histochem Cell Biol 2001 Jul;116(1):31-9       26 Citations
1Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. (Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH) Cancer 2001 Jul 15;92(2):406-13       262 Citations
1Anti-CD3 epsilon F(ab')2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens. (Yu XZ, Bidwell SJ, Martin PJ, Anasetti C) J Immunol 2001 May 01;166(9):5835-9       33 Citations
2Inhibition of antigen-receptor signaling by Platelet Endothelial Cell Adhesion Molecule-1 (CD31) requires functional ITIMs, SHP-2, and p56(lck). (Newman DK, Hamilton C, Newman PJ) Blood 2001 Apr 15;97(8):2351-7       121 Citations
1Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors. (Ewenstein BM, Hoots WK, Lusher JM, DiMichele D, White GC 2nd, Adelman B, Nadeau K) Haematologica 2000 Oct;85(10 Suppl):35-9       32 Citations
1Cholinergic basal forebrain is critical for social transmission of food preferences. (Berger-Sweeney J, Stearns NA, Frick KM, Beard B, Baxter MG) Hippocampus 2000;10(6):729-38       68 Citations
1Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. (Ozkaynak MF, Sondel PM, Krailo MD, Gan J, Javorsky B, Reisfeld RA, Matthay KK, Reaman GH, Seeger RC) J Clin Oncol 2000 Dec 15;18(24):4077-85       180 Citations
1Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. (Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG) Am J Gastroenterol 2000 Nov;95(11):3189-94       234 Citations
1Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. (Carpenter PA, Pavlovic S, Tso JY, Press OW, Gooley T, Yu XZ, Anasetti C) J Immunol 2000 Dec 01;165(11):6205-13       95 Citations
1Inflammatory response and angiogenesis after percutaneous transmyocardial laser revascularization. (Bortone AS, D'Agostino D, Schena S, Rubini G, Brindicci P, Sardaro V, D'Addabbo A, de Luca Tupputi Schinosa L) Ann Thorac Surg 2000 Sep;70(3):1134-8       15 Citations
1Preparation of Der p 1 specific monoclonal antibodies and use in a two-site-ELISA to detect Der p 1 allergen. (Chien TI, Chen YG, Chiang BL) J Microbiol Immunol Infect 2000 Jun;33(2):87-92       3 Citations
1Surface expression of glycoprotein ib alpha is dependent on glycoprotein ib beta: evidence from a novel mutation causing Bernard-Soulier syndrome. (Moran N, Morateck PA, Deering A, Ryan M, Montgomery RR, Fitzgerald DJ, Kenny D) Blood 2000 Jul 15;96(2):532-9       61 Citations
1Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. (Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ, Radinsky R) Clin Cancer Res 2000 May;6(5):1936-48       435 Citations
1CD28-specific antibody prevents graft-versus-host disease in mice. (Yu XZ, Bidwell SJ, Martin PJ, Anasetti C) J Immunol 2000 May 01;164(9):4564-8       79 Citations
1Expression and function of calcium binding domain chimeras of the integrins alpha(IIb) and alpha(5). (Gidwitz S, Lyman S, White GC 2nd) J Biol Chem 2000 Mar 03;275(9):6680-8       4 Citations
1Reversal of drug resistance in sarcoma-45 by the new calmodulin antagonist--trihydrochloride of [1,2,5-trimethyl-4-phenyl-4-beta-[N-(beta-ethylamino)-N-4'-methoxybe nzy l]-ethylamino] piperidine (AR-2). (Alexanian AR, Arutyunian NS) Invest New Drugs 1999;17(2):105-10       3 Citations
1Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. (Uckun FM, Messinger Y, Chen CL, O'Neill K, Myers DE, Goldman F, Hurvitz C, Casper JT, Levine A) Clin Cancer Res 1999 Dec;5(12):3906-13       71 Citations
1Murine CCR9, a chemokine receptor for thymus-expressed chemokine that is up-regulated following pre-TCR signaling. (Norment AM, Bogatzki LY, Gantner BN, Bevan MJ) J Immunol 2000 Jan 15;164(2):639-48       95 Citations
2Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy. (Johnson BD, Becker EE, LaBelle JL, Truitt RL) J Immunol 1999 Dec 15;163(12):6479-87       63 Citations
1A new molecular link between the fibrillar and granulovacuolar lesions of Alzheimer's disease. (Ghoshal N, Smiley JF, DeMaggio AJ, Hoekstra MF, Cochran EJ, Binder LI, Kuret J) Am J Pathol 1999 Oct;155(4):1163-72       136 Citations
1The anti-factor D antibody, MAb 166-32, inhibits the alternative pathway of the human complement system. (Tanhehco EJ, Kilgore KS, Liff DA, Murphy KL, Fung MS, Sun WN, Sun C, Lucchesi BR) Transplant Proc 1999 Aug;31(5):2168-71       18 Citations
1Alteration of sialyl Lewis epitope expression in pterygium. (Creuzot-Garcher C, Guerzider V, Assem M, Bron AM, Delannoy P, Bara J) Invest Ophthalmol Vis Sci 1999 Jul;40(8):1631-6       17 Citations
1Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. (Huang SM, Bock JM, Harari PM) Cancer Res 1999 Apr 15;59(8):1935-40       722 Citations
1Characterization of monoclonal antibodies against hepatitis C virus nonstructural protein 3: different antigenic determinants from human B cells. (Ou-Yang P, Chiang BL, Hwang LH, Chen YG, Yang PM, Chi WK, Chen PJ, Chen DS) J Med Virol 1999 Apr;57(4):345-50       7 Citations
1p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. (Zheng W, Khurana R, Farahmand S, Wang Y, Zhang ZF, Felix JC) Am J Surg Pathol 1998 Dec;22(12):1463-73       93 Citations
2Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. (Hale G, Zhang MJ, Bunjes D, Prentice HG, Spence D, Horowitz MM, Barrett AJ, Waldmann H) Blood 1998 Dec 15;92(12):4581-90       175 Citations
1An antibody from a patient with ranitidine-induced thrombocytopenia recognizes a site on glycoprotein IX that is a favored target for drug-induced antibodies. (Gentilini G, Curtis BR, Aster RH) Blood 1998 Oct 01;92(7):2359-65       52 Citations
1CD14-dependent activation of human endothelial cells by Bacteroides fragilis outer membrane. (Sato TT, Kovacich JC, Boyle EM Jr, Haddix TL, Weintraub A, Pohlman TH) J Surg Res 1998 Feb 01;74(2):103-11       7 Citations
1The c-kit receptor and its possible signaling transduction pathway in mouse spermatozoa. (Feng H, Sandlow JI, Sandra A) Mol Reprod Dev 1998 Mar;49(3):317-26       48 Citations
1Injury to the Ca2+ ATPase of the sarcoplasmic reticulum in anesthetized dogs contributes to myocardial reperfusion injury. (Smart SC, Sagar KB, el Schultz J, Warltier DC, Jones LR) Cardiovasc Res 1997 Nov;36(2):174-84       20 Citations
1Antigenic structure, function, and evolution of the hemagglutinin-neuraminidase protein of human parainfluenza virus type 1. (Henrickson KJ, Savatski LL) J Infect Dis 1997 Oct;176(4):867-75       19 Citations
1Expression and function of the c-kit proto-oncogene protein in mouse sperm. (Feng H, Sandlow JI, Sandra A) Biol Reprod 1997 Jul;57(1):194-203       33 Citations
1Expression of cyclin protein after thermal skin injury in a guinea pig model. (DeCherney AH, Dougherty WR, Felix JC, Rodgers KE, Girgis W, Abiko M, diZerega GS) J Burn Care Rehabil 1997;18(4):292-8       4 Citations
1Identification and molecular cloning of a 67-kilodalton protein in Schistosoma japonicum homologous to a family of actin-binding proteins. (Kurtis JD, Ramirez BL, Wiest PM, Dong KL, El-Meanawy A, Petzke MM, Johnson JH, Edmison J, Maier RA Jr, Olds GR) Infect Immun 1997 Jan;65(1):344-7       14 Citations
1Endometrial glandular proliferation and estrogen receptor content during the normal menstrual cycle. (Felix JC, Farahmand S) Contraception 1997 Jan;55(1):19-22       23 Citations
1Engagement of the Lewis X antigen (CD15) results in monocyte activation. (Lo SK, Golenbock DT, Sass PM, Maskati A, Xu H, Silverstein RL) Blood 1997 Jan 01;89(1):307-14       39 Citations
1Constructional apraxia in Alzheimer's disease correlates with neuritic neuropathology in occipital cortex. (Nielson KA, Cummings BJ, Cotman CW) Brain Res 1996 Nov 25;741(1-2):284-93       36 Citations
1Induction of apoptosis by anti-CD3 epsilon F(ab')2 in antigen receptor transgenic murine T cells activated by specific peptide. (Yu XZ, Zhu L, Davis JE, Tso JY, Hansen JA, Anasetti C) J Immunol 1996 Oct 15;157(8):3420-9       20 Citations
2Human adenovirus-specific CD8+ T-cell responses are not inhibited by E3-19K in the presence of gamma interferon. (Flomenberg P, Piaskowski V, Truitt RL, Casper JT) J Virol 1996 Sep;70(9):6314-22       51 Citations
1Tumor necrosis factor-induced E-selectin expression on vascular endothelial cells. (Gedeit RG) Crit Care Med 1996 Sep;24(9):1543-6       16 Citations
2Cytokine inhibition preserves renal hemodynamic function following mesangial cell immune injury. (Pan CG, Bresnahan BA, Albrightson CR, Griswold D, Lianos EA) J Investig Med 1996 Aug;44(6):375-81       7 Citations
1Retinoic acid stimulates pyrophosphate elaboration by cartilage and chondrocytes. (Rosenthal AK, Henry LA) Calcif Tissue Int 1996 Aug;59(2):128-33       15 Citations
1Hypothermia inhibits human E-selectin transcription. (Haddix TL, Pohlman TH, Noel RF, Sato TT, Boyle EM Jr, Verrier ED) J Surg Res 1996 Aug;64(2):176-83       45 Citations
1Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts. (Drobyski WR, Majewski D) Blood 1996 Jun 15;87(12):5355-69       11 Citations
1Inhibition of platelet adhesion to collagen by monoclonal anti-CD36 antibodies. (Matsuno K, Diaz-Ricart M, Montgomery RR, Aster RH, Jamieson GA, Tandon NN) Br J Haematol 1996 Mar;92(4):960-7       60 Citations
1A monoclonal natural autoantibody that promotes remyelination suppresses central nervous system inflammation and increases virus expression after Theiler's virus-induced demyelination. (Miller DJ, Njenga MK, Murray PD, Leibowitz J, Rodriguez M) Int Immunol 1996 Jan;8(1):131-41       29 Citations
1Tumor antigens in astrocytic gliomas. (Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD) Glia 1995 Nov;15(3):244-56       107 Citations
1Soluble T cell receptors: detection and quantitative assay in fluid phase via ELISA or immuno-PCR. (Sperl J, Paliwal V, Ramabhadran R, Nowak B, Askenase PW) J Immunol Methods 1995 Oct 26;186(2):181-94       26 Citations
1Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. (Reist CJ, Archer GE, Kurpad SN, Wikstrand CJ, Vaidyanathan G, Willingham MC, Moscatello DK, Wong AJ, Bigner DD, Zalutsky MR) Cancer Res 1995 Oct 01;55(19):4375-82       111 Citations
1Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. (Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ) Cancer Res 1995 Jul 15;55(14):3140-8       483 Citations
1Adoptive cell transfer of contact sensitivity-initiation mediated by nonimmune cells sensitized with monoclonal IgE antibodies. Dependence on host skin mast cells. (Matsuda H, Ushio H, Paliwal V, Ptak W, Askenase PW) J Immunol 1995 May 15;154(10):5080-92       18 Citations
1Safety of high doses of a monoclonal antibody-purified factor IX concentrate. The Mononine Study Group. (Warrier I, Kasper CK, White GC 2nd, Shapiro AD, Bergman GE) Am J Hematol 1995 May;49(1):92-4       7 Citations
1Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group. (White GC 2nd, Shapiro AD, Kurczynski EM, Kim HC, Bergman GE) Thromb Haemost 1995 May;73(5):779-84       36 Citations
1Gamma delta T cells in normal spleen assist immunized alpha beta T cells in the adoptive cell transfer of contact sensitivity. Effect of Bordetella pertussis, cyclophosphamide, and antibodies to determinants on suppressor cells. (Askenase PW, Szczepanik M, Ptak M, Paliwal V, Ptak W) J Immunol 1995 Apr 15;154(8):3644-53       40 Citations
1Tyrosine kinase activity of the EGF receptor in murine metanephric organ culture. (Pugh JL, Sweeney WE Jr, Avner ED) Kidney Int 1995 Mar;47(3):774-81       54 Citations
1How a collaborative task force can assist in managing biotechnology products. (MacKinnon GE 3rd) Hosp Formul 1994 Jul;29(7):526-30, 533    
1Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates. (Cadroy Y, Hanson SR, Kelly AB, Marzec UM, Evatt BL, Kunicki TJ, Montgomery RR, Harker LA) Blood 1994 Jun 01;83(11):3218-24       70 Citations
1Factor VIII inhibitor assay: quantitative and qualitative assay limitations and development needs. (White GC 2nd) Semin Hematol 1994 Apr;31(2 Suppl 4):6-10       8 Citations
1CD antigens 1993. (Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein RL, Springer TA) Blood 1994 Feb 15;83(4):879-80       29 Citations
1Corneal synthesis of alpha 1-proteinase inhibitor (alpha 1-antitrypsin). (Twining SS, Fukuchi T, Yue BY, Wilson PM, Boskovic G) Invest Ophthalmol Vis Sci 1994 Feb;35(2):458-62       56 Citations
1Low retention of white cell fragments by polyester fiber white cell-reduction platelet filters. (Ramos RR, Curtis BR, Duffy BF, Chaplin H) Transfusion 1994 Jan;34(1):31-4       26 Citations
1Induction of porcine granulocyte-mediated tumor cytotoxicity by two distinct monoclonal antibodies against lytic trigger molecules (PNK-E/G7). (Wierda WG, Johnson BD, Dato ME, Kim YB) J Immunol 1993 Dec 15;151(12):7117-27       16 Citations
1Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer's disease. (Bennett DA, Cochran EJ, Saper CB, Leverenz JB, Gilley DW, Wilson RS) Neurobiol Aging 1993;14(6):589-96       63 Citations
1Integrin alpha IIb beta 3 mediates binding of the Lyme disease agent Borrelia burgdorferi to human platelets. (Coburn J, Leong JM, Erban JK) Proc Natl Acad Sci U S A 1993 Aug 01;90(15):7059-63       152 Citations
1Gamma-tubulin in differentiated cell types: localization in the vicinity of basal bodies in retinal photoreceptors and ciliated epithelia. (Muresan V, Joshi HC, Besharse JC) J Cell Sci 1993 Apr;104 ( Pt 4):1229-37       100 Citations
1Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. (Estrov Z, Kurzrock R, Pocsik E, Pathak S, Kantarjian HM, Zipf TF, Harris D, Talpaz M, Aggarwal BB) J Exp Med 1993 Mar 01;177(3):763-74       84 Citations
1Two distinct porcine natural killer lytic trigger molecules as PNK-E/G7 molecular complex. (Wierda WG, Johnson BD, Dato ME, Kim YB) Cell Immunol 1993 Feb;146(2):270-83       13 Citations
2Distinguishing unloading- versus reloading-induced changes in rat soleus muscle. (Krippendorf BB, Riley DA, New Collective Author) Muscle Nerve 1993 Jan;16(1):99-108       82 Citations
1Identification of lysosome-associated membrane protein-2 as an activation-dependent platelet surface glycoprotein. (Silverstein RL, Febbraio M) Blood 1992 Sep 15;80(6):1470-5       85 Citations
1Human monoclonal striational autoantibodies isolated from thymic B lymphocytes of patients with myasthenia gravis use VH and VL gene segments associated with the autoimmune repertoire. (Victor KD, Pascual V, Williams CL, Lennon VA, Capra JD) Eur J Immunol 1992 Sep;22(9):2231-6       23 Citations
1Sense and antisense cDNA transfection of CD36 (glycoprotein IV) in melanoma cells. Role of CD36 as a thrombospondin receptor. (Silverstein RL, Baird M, Lo SK, Yesner LM) J Biol Chem 1992 Aug 15;267(23):16607-12       86 Citations
1Regulatory effects of gallium on transferrin-independent iron uptake by human leukemic HL60 cells. (Chitambar CR, Sax D) Blood 1992 Jul 15;80(2):505-11       51 Citations
1A latex particle assay for platelet-associated IgG. (Ramos RR, Curtis BR, Chaplin H) Transfusion 1992;32(3):235-8       7 Citations
2Cell polarity and calcium oxalate crystal adherence to cultured collecting duct cells. (Riese RJ, Mandel NS, Wiessner JH, Mandel GS, Becker CG, Kleinman JG) Am J Physiol 1992 Feb;262(2 Pt 2):F177-84       95 Citations
1Onset of expression and regional deposition of alpha-smooth and sarcomeric actin during avian heart development. (Sugi Y, Lough J) Dev Dyn 1992 Feb;193(2):116-24       58 Citations
1Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. (Kim HC, McMillan CW, White GC, Bergman GE, Horton MW, Saidi P) Blood 1992 Feb 01;79(3):568-75       84 Citations
1Fine mapping of monoclonal antibody epitopes on human von Willebrand factor using a recombinant peptide library. (Ginsburg D, Bockenstedt PL, Allen EA, Fox DA, Foster PA, Ruggeri ZM, Zimmerman TS, Montgomery RR, Bahou WF, Johnson TA) Thromb Haemost 1992 Jan 23;67(1):166-71       20 Citations
1Monoclonal antibodies to human parainfluenza virus type 1 detect major antigenic changes in clinical isolates. (Henrickson KJ) J Infect Dis 1991 Dec;164(6):1128-34       12 Citations
2The rapid differentiation of type IIb von Willebrand's disease from platelet-type (pseudo-) von Willebrand's disease by the "neutral" monoclonal antibody binding assay. (Scott JP, Montgomery RR) Am J Clin Pathol 1991 Dec;96(6):723-8       34 Citations
1Mesangial cell immune injury. Synthesis, origin, and role of eicosanoids. (Lianos EA, Bresnahan BA, Pan C) J Clin Invest 1991 Aug;88(2):623-31       52 Citations
1Antibody recognition of an immunogenic influenza hemagglutinin-human leukocyte antigen class II complex. (Nygard NR, Bono C, Brown LR, Gorka J, Giacoletto KS, Schaiff WT, Graham MB, McCourt DW, Kabeer M, Braciale VL) J Exp Med 1991 Jul 01;174(1):243-51       19 Citations
1Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients. (Drobyski WR, Gottlieb M, Carrigan D, Ostberg L, Grebenau M, Schran H, Magid P, Ehrlich P, Nadler PI, Ash RC) Transplantation 1991 Jun;51(6):1190-6       29 Citations
1Antibodies that neutralize human beta interferon biologic activity recognize a linear epitope: analysis by synthetic peptide mapping. (Redlich PN, Hoeprich PD Jr, Colby CB, Grossberg SE) Proc Natl Acad Sci U S A 1991 May 01;88(9):4040-4       40 Citations
1Further characterization of PNK-E: a monoclonal antibody enhancing porcine natural killer cell activity. (Johnson BD, Wierda WG, Kim YB) Cell Immunol 1991 May;134(2):378-89       11 Citations
1The role of microfilaments in the capping of epidermal growth factor receptor in A431 cells. (Khrebtukova IA, Kwiatkowska K, Gudkova DA, Sorokin AB, Pinaev GP) Exp Cell Res 1991 May;194(1):48-55       13 Citations
1CD36-mediated signal transduction in human monocytes by anti-CD36 antibodies but not by anti-thrombospondin antibodies recognizing cell membrane-bound thrombospondin. (Schüepp BJ, Pfister H, Clemetson KJ, Silverstein RL, Jungi TW) Biochem Biophys Res Commun 1991 Feb 28;175(1):263-70       45 Citations
1Serotonin initiation of delayed-type hypersensitivity: mediation by a primitive Thy-1+ antigen-specific clone or by specific monoclonal IgE antibody. (Askenase PW, Herzog WR, Millet I, Paliwal V, Ramabhadran R, Rochester C, Geba GP, Ptak W) Skin Pharmacol 1991;4 Suppl 1:25-42       27 Citations
2Developing neural crest cells in culture: correlation of cytochrome oxidase activity with SSEA-1 and dopamine-beta-hydroxylase immunoreactivity. (Liu S, Wilcox DA, Sieber-Blum M, Wong-Riley M) Brain Res 1990 Dec 10;535(2):271-80       7 Citations
1Meningism in a ten-month-old infant during OKT3 therapy. (Rizzo JD, Rowe SA) J Heart Transplant 1990;9(6):727-8       2 Citations
1Immunochemical characterization of antigenic domains on human interferon-beta: spatially distinct epitopes are associated with both antiviral and antiproliferative activities. (Redlich PN, Grossberg SE) Eur J Immunol 1990 Sep;20(9):1933-9       12 Citations
2Elimination of OX8+ cells prolongs cardiac but not pancreatic allograft survival across minor (non-MHC) histocompatibility barriers. (Roza AM, Johnson CP, Adams MB, Naji A) Transplant Proc 1990 Apr;22(2):747-8       1 Citation
1Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B. (Kim HC, McMillan CW, White GC, Bergman GE, Saidi P) Semin Hematol 1990 Apr;27(2 Suppl 2):30-5       25 Citations
1PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. (Newman PJ, Berndt MC, Gorski J, White GC 2nd, Lyman S, Paddock C, Muller WA) Science 1990 Mar 09;247(4947):1219-22       906 Citations
1Antibody response in children to antigen sites on human PIV-3 HN: correlation with known epitopes mapped by monoclonal antibodies. (Henrickson KJ, Portner A) Vaccine 1990 Feb;8(1):75-80       9 Citations
1A human monoclonal autoantibody specific for human platelet glycoprotein IIb (integrin alpha IIb) heavy chain. (Kunicki TJ, Furihata K, Kekomaki R, Scott JP, Nugent DJ) Hum Antibodies Hybridomas 1990;1(2):83-95       24 Citations
1Immunosuppressive therapy for aplastic anemia: indications, agents, mechanisms, and results. (Camitta BM, Doney K) Am J Pediatr Hematol Oncol 1990;12(4):411-24       38 Citations
1Transmembrane assemblage of the photoreceptor connecting cilium and motile cilium transition zone contain a common immunologic epitope. (Horst CJ, Johnson LV, Besharse JC) Cell Motil Cytoskeleton 1990;17(4):329-44       62 Citations
1Characterization of a monoclonal antibody enhancing porcine natural killer cell activity (PNK-E). (Johnson BD, Kim YB) Cell Immunol 1990 Jan;125(1):107-19       16 Citations
1Thrombolamban, the 22-kDa platelet substrate of cyclic AMP-dependent protein kinase, is immunologically homologous with the Ras family of GTP-binding proteins. (White TE, Lacal JC, Reep B, Fischer TH, Lapetina EG, White GC 2nd) Proc Natl Acad Sci U S A 1990 Jan;87(2):758-62       32 Citations
1The identification of sarcoplasmic reticulum terminal cisternae proteins in platelets. (Fischer TH, Barton DW, Krause KH, White TE, Campbell KP, White GC 2nd) Biochem J 1989 Oct 15;263(2):605-8    
1[The capping of receptors for the epidermal growth factor and the participation of the cytoskeleton in this process in A-431 cells]. (Khrebtukova IA, Nikol'skaia AN, Sorkin AD, Sorokin AB, Pinaev GP) Tsitologiia 1989 Oct;31(10):1211-20       1 Citation
1Analysis of antigenic domains on natural and recombinant human IFN-beta by the inhibition of biologic activities with monoclonal antibodies. (Redlich PN, Grossberg SE) J Immunol 1989 Sep 15;143(6):1887-93       20 Citations
1Effect of prolonged monoclonal antibody administration on cardiac allograft survival in the rat. (Roza AM, Kimura H, Markmann J, Naji A) Scand J Immunol 1989 Sep;30(3):333-8       11 Citations
1Glycoprotein IV mediates thrombospondin-dependent platelet-monocyte and platelet-U937 cell adhesion. (Silverstein RL, Asch AS, Nachman RL) J Clin Invest 1989 Aug;84(2):546-52       179 Citations
1Release of soluble transferrin receptor from the surface of human leukemic HL60 cells. (Chitambar CR, Zivkovic Z) Blood 1989 Aug 01;74(2):602-8       37 Citations
1[Isolation and characteristics of monoclonal antibodies to the external domain of the EGF receptor in human A431 epidermoid carcinoma]. (Sorokin AB, Nesterov AM, Sorkin AD, Ignatova TN, Galaktionov KI) Tsitologiia 1989 May;31(5):549-55       5 Citations
1Characterization of nonmotile neutrophil subpopulations in neonates and adults. (Krause PJ, Kreutzer DL, Eisenfeld L, Herson VC, Weisman S, Bannon P, Greca N) Pediatr Res 1989 May;25(5):519-24       22 Citations
2Effect of elimination of OX-19+ and OX-8+ T-cell subsets upon pancreatic allograft survival. (Roza AM, Markmann JF, Kimura H, Johnson CP, Adams MB, Naji A) J Surg Res 1989 Apr;46(4):395-9       1 Citation
1Localization and quantification of alpha-1-proteinase inhibitor in the human cornea. (Twining SS, Everse SJ, Wilson PM, Yue BY, Chan SK) Curr Eye Res 1989 Apr;8(4):389-95       13 Citations
1Basal lamina components are concentrated in premuscle masses and at early acetylcholine receptor clusters in chick embryo hindlimb muscles. (Godfrey EW, Siebenlist RE, Wallskog PA, Walters LM, Bolender DL, Yorde DE) Dev Biol 1988 Dec;130(2):471-86       67 Citations
1The classical and alternate pathways of T cell activation are impaired in leprosy. (Muthukkaruppan V, Chakkalath HR, Malarkannan S) Immunol Lett 1988 Sep;19(1):55-8       4 Citations
1Regulation of glucocorticoid receptors and Na-K ATPase activity by hydrocortisone in proximal tubular epithelial cells. (Ellis D, Sothi TD, Curthoys NP, Ballou B, Avner ED) In Vitro Cell Dev Biol 1988 Aug;24(8):811-6       4 Citations
1[The removal of HLA DR antigens in human epidermis by complement dependent monoclonal antibody mediated cytotoxicity--a preliminary report]. (Chiang SS, Fang RH, King YH, Dzwierzynski W, Gottlieb LJ, Ma A, Krizek TJ) Zhonghua Yi Xue Za Zhi (Taipei) 1988 Jul;42(1):17-22    
1Two smooth muscle myosin heavy chains differ in their light meromyosin fragment. (Eddinger TJ, Murphy RA) Biochemistry 1988 May 17;27(10):3807-11       67 Citations
1In vitro differentiation of quail neural crest cells into sensory-like neuroblasts. (Sieber-Blum M, Kumar SR, Riley DA) Brain Res 1988 Mar 01;467(1):69-83       13 Citations
1Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon. (Hanson SR, Pareti FI, Ruggeri ZM, Marzec UM, Kunicki TJ, Montgomery RR, Zimmerman TS, Harker LA) J Clin Invest 1988 Jan;81(1):149-58       135 Citations
1Distribution of acetylated alpha-tubulin in retina and in vitro-assembled microtubules. (Sale WS, Besharse JC, Piperno G) Cell Motil Cytoskeleton 1988;9(3):243-53       81 Citations
1Elimination of clonogenic malignant human T cells using monoclonal antibodies in combination with 2'-deoxycoformycin. (Schwartz CL, Minniti CP, Harwood P, Na S, Banquerigo ML, Strauss LC, Kurtzberg J, Smith SD, Civin CI) J Clin Oncol 1987 Dec;5(12):1900-11       5 Citations
1Uptake of gallium-67 by human leukemic cells: demonstration of transferrin receptor-dependent and transferrin-independent mechanisms. (Chitambar CR, Zivkovic Z) Cancer Res 1987 Aug 01;47(15):3929-34       131 Citations
1Isolation of the thrombospondin membrane receptor. (Asch AS, Barnwell J, Silverstein RL, Nachman RL) J Clin Invest 1987 Apr;79(4):1054-61       451 Citations
1Manipulation of T-cell content in transplanted human bone marrow: effect on GVH and GVL reactions. (Truitt RL, Ash RC) Prog Clin Biol Res 1987;244:409-21       16 Citations
1Synthesis by cultured human umbilical vein endothelial cells of two proteins structurally and immunologically related to platelet membrane glycoproteins IIb and IIIa. (Newman PJ, Kawai Y, Montgomery RR, Kunicki TJ) J Cell Biol 1986 Jul;103(1):81-6       39 Citations
1Development of a simplified counterflow centrifugation elutriation procedure for depletion of lymphocytes from human bone marrow. (Noga SJ, Donnenberg AD, Schwartz CL, Strauss LC, Civin CI, Santos GW) Transplantation 1986 Feb;41(2):220-9       38 Citations
1Use of monoclonal antibody to increase the sensitivity and specificity of precipitating immunoassays and cell surface binding immunoassays. (Montgomery RR, Kunicki TJ, Glode LM) Methods Enzymol 1986;121:702-17       10 Citations
1Lymphocyte function-associated antigen 1 (LFA-1) contains sulfated N-linked oligosaccharides. (Dahms NM, Hart GW) J Immunol 1985 Jun;134(6):3978-86       27 Citations
1Surface antigens of Bordetella pertussis. (Parker CD, Armstrong SK, Frank DW) Adv Exp Med Biol 1985;185:117-27    
1Cell surface antigens of Bordetella pertussis. (Parker CD, Branes LV, Armstrong SK, Frank DW, Cole A) Dev Biol Stand 1985;61:123-36       2 Citations
1Evaluation of lymphocyte subsets and suppressor cell function in long-term renal transplant recipients. (Redlich PN, Leapman SB, Marder P, Schmidtke J, Smith EJ, Fineberg N, Filo RS) Transplant Proc 1984 Dec;16(6):1555-7       1 Citation
1Interaction of monoclonal antibodies with pertussis toxin and its subunits. (Frank DW, Parker CD) Infect Immun 1984 Oct;46(1):195-201       18 Citations
1Isolation and characterization of monoclonal antibodies to Bordetella pertussis. (Frank DW, Parker CD) J Biol Stand 1984 Oct;12(4):353-65       11 Citations
1Interaction of von Willebrand factor with human platelets in the plasma milieu. (Schullek J, Jordan J, Montgomery RR) J Clin Invest 1984 Feb;73(2):421-8       79 Citations
1Interaction of AP-2, a monoclonal antibody specific for the human platelet glycoprotein IIb-IIIa complex, with intact platelets. (Pidard D, Montgomery RR, Bennett JS, Kunicki TJ) J Biol Chem 1983 Oct 25;258(20):12582-6       268 Citations
1Regulation of transferrin receptor expression on human leukemic cells during proliferation and induction of differentiation. Effects of gallium and dimethylsulfoxide. (Chitambar CR, Massey EJ, Seligman PA) J Clin Invest 1983 Oct;72(4):1314-25       130 Citations
1Diagnosis of Bernard-Soulier syndrome and Glanzmann's thrombasthenia with a monoclonal assay on whole blood. (Montgomery RR, Kunicki TJ, Taves C, Pidard D, Corcoran M) J Clin Invest 1983 Feb;71(2):385-9    
1Pharmacological modification of immunoregulatory T lymphocytes . II. Modulation of T lymphocyte cell surface characteristics. (Birch RE, Rosenthal AK, Polmar SH) Clin Exp Immunol 1982 Apr;48(1):231-8       42 Citations
1Use of monoclonal antibody to increase sensitivity and specificity in quantitative immunodiffusion assays. (Glode LM, Montgomery RR, Smith CG, Link DB) J Immunol Methods 1982;48(1):13-22       5 Citations